A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008) (Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)



ATHENS MEDICAL CENTER S.A.

A' SIX MONTH FINANCIAL REPORT

(1 January – 30 June 2008)

According to L. 3556/2007 article 5

ATHENS MEDICAL CENTER S.A.

A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

CONTENTS OF A' SIX MONTH FINANCIAL REPORT (According to L. 3556/2007 article 5 and the 1/434/3.7.2007, 7/448/11.10.2007 decisions of the Capital Market's Board of Directors Commission)

	<u>Page</u>
Statements of the Board of Directors' Members	3
Report of the Board of Directors	4-8
Report on Review of Interim Financial Information	9-10
Interim Financial Statements	11-50
Financial Results	51

A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008)

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

STATEMENTS OF MEMBERS OF THE BOARD (IN ACCORDANCE WITH ARTICLE 5 PAR. 2 OF LAW. 3556/2007)

The members of the Board of Directors of «ATHENS MEDICAL CENTER S.A.» declare that as far as we know:

- a. The Financial Statements for the 1st half of 2008 of parent company and group, which were drawn up in accordance with applicable International Financial Reporting Standards, reflect in a true manner the assets and liabilities, equity and results of «ATHENS MEDICAL CENTER S.A.», as well as of the companies included in the consolidation, taken as a whole, in accordance with the provisions of paragraphs 3 to 5 of article 5 of Law 3556/2007 and
- β. the A' six month report of the Board of Directors contains the true information required by paragraph 6 of article 5 of Law 3556/2007.

Maroussi 25/8/2008

THE PRESIDENT OF THE B.O.D.	THE CEO	THE VICE PRESIDENT		
G.V. APOSTOLOPOULOS	V.G.APOSTOLOPOULOS	H.G. APOSTOLOPOULOS		
ID NUMBER Σ 100951	ID NUMBER = 350622	ID NUMBER P 519481		

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

1st HALF YEAR REPORT OF THE BOARD OF DIRECTORS

FINANCIAL FIGURES – BUSINESS PROGRESS

The turnover of the Group of Athens Medical Center over the 1st HY of 2008 amounted to 148 million Euro, showing a reduction of 1,43% compared to the corresponding period of 2007. The operating profit before taxes, interest and depreciation (EBIDTA) for the same period amounted to 23,9 million Euro, reduced by 7,7% compared to the corresponding EBIDTA of 2007. The Group's net income after minority rights and taxes amounted to 9,9 million Euro, reduced by 18,01% compared to the corresponding period of 2007.

The slow down of the financial results is due to 3 factors: a) The initiation of operation of Peristeri Clinic at the beginning of the year, which still operates with low capacity whilst the fixed expenses negatively affect the clinic's profitability, b) The payroll cost increase by 13,37% compared to 2007, which was undertaken because it directly reflects on the quality of services provided to the hospitalized patients of the Group's hospitals, and c) The imposition of maximum prices on medical supplies by the insurance funds.

Abroad, the Group is active in Romania through its subsidiary Medsana Bucharest and particularly in Bucharest with two (2) diagnostic centers and in Ploesti with one (1) diagnostic center which initiated its operation a month ago. The activity of Romania's subsidiary during the first HY of 2008 is strengthened; turnover is increased by 12% compared to the first HY of 2007. The subsidiary's net profit amounted to 390 thousand Euro, decreased by 7% compared to the corresponding period of 2007.

EXPANSION OF ACTIVITIES

For the time being the Group is developing its activity in Romania, where it has been active for 10 years and has earned the trust of the public. The Group has decided to expand its activity and operate a hospital in Bucharest. This decision will be implemented either by building a new hospital with capacity of 150 beds, or by acquiring EUREKO'S Group operating hospital which is subject to an international auction process. The auction is still in process. The Group has submitted its bid to the Agent which handles the competition and the final decision of the seller is expected. Depending on this decision, the Group will proceed to its next moves in Romania.

Within the Group, Daphne's Artificial Kidney Unit transforamtion to a General Clinic is scheduled. The necessary adjustments and the purchase of equipment have been made in order for the clinic to be commensurate to the other clinics of the Group. Thus the entire area of Attica will be covered by Athens Medical Group's clinics.

The Group acts so as to maintain the competitive advantage in the area of private sector in primary and secondary hospitalization and at the same time is contracting with Insurance Companies in order to become more attractive to the population that maintains private insurance. In the 1st HY of 2008 the Group contracted with 3 of the largest Insurance Companies in Greece, specifically AXA Insurance, GROUPAMA-METROLIFE and GENERALI LIFE, for the total of the hospitals. In July 2008 the Group signed a contract with AGROTIKI INSURANCE as well. It is noted that these agreements are the first universal agreements that the Group enters into since the termination of the agreement with the Union of the Insurance Companies in July 2002.

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

PERSPECTIVES FOR THE 2ND HALF YEAR OF 2008

An improvement is expected for the 2nd HY of 2008 in regard with the corresponding period of the previous year. The improvement will stem from the increased capacity of Peristeri Clinic which begins collaborations with Pension Funds and doctors with known prestige as well as the expected increase of the capacity utilization of the other hospitals after the above mentioned collaboration with the Insurance Companies.

RISKS AND UNCERTAINTIES FOR THE 2nd HALF OF 2008

1. Counterparty Risk

The counterparties of the group are Pension Funds, Insurance Companies and private individuals. Concerning Pension Funds, the risk is essentially Greek State risk. The Group believes that there is no likelihood that the obligations of the Funds towards its units will not be honoured, and the uncertainty extends only to the time of repayment. In all the hospitals of the Group exists specialized personnel entrusted with following carefully the transactions with the Pension Funds.

Concerning Insurance Companies, the Companies with which the Group has entered into contractual agreements are financially strong and we do not foresee the likelihood of non-service. Additionally, as has been made public, the Union of Insurance Companies is making systematic efforts to boost the reserves of its members. This will lead to concentration in the sector and, thus, to stronger Insurance Companies.

Concerning private individuals, their number and dispersion is such that the estimated risk of non-service is very small.

2. Interest Rate Risk

The Company has issued a long-term common Bond Loan of \in 150 million, which is subject to floating interest rate based on Euribor. The total burden due to interest expense for the 1st half of 2008 was \in 4,9 million. Therefore the Company is exposed to interest rate risk, which may have a significant influence on its profitability. It is noted that interbank rates, such as Euribor, are much higher that the central ECB rate and follow an increasing trend.

Within the 1st half of 2008, the Company contracted a number of derivative products for liability management, with which it significantly decreases its borrowing costs by undertaking reasonable and limited risk. Moreover, the risk of some of those products co-varies in an inverse manner, thus offering a fairly stable aggregate coverage.

3. Exchange Rate Risk

The Company is active abroad through its subsidiary Medsana Bucharest. The exchange rate risk due to the movement of the RON/ \in rate, and its effect on the profitability of the subsidiary expressed in \in , is small and not worthy of hedging.

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

4. Liquidity Risk

The hospitals of the Group follow carefully the maturing of their liabilities and receivables and are acting so as not to find themselves in a situation of inadequate liquidity. This is done by adjusting, to the extent possible, the turnover of their liabilities so as not to diverge significantly from the turnover of their receivables. Apart from that, the Group maintains adequate credit lines with financial institutions, to which it may have recourse if it is deemed necessary.

NOTIFICATIONS OF RELATED PARTIES

The Company and its subsidiaries are related to the following legal entities and physical persons:

- Due to majority participation in its capital, with Mr George Apostolopoulos and the legal entities or business activities he is part of
- With its subsidiaries, including their main shareholders and the members of their Boards of Directors
- With the members of its Board of Directors

Group (Subsidiaries)

The transactions with its subsidiaries mainly refer to the provision of commercial services, as well as the purchase and sale of merchandise. The transactions are part of the normal course of operation of the Company.

The relevant outstanding balances from related companies are not covered by collateral and their repayment is effected through cash payments within time frames agreed between the companies. The Management of the Company does not believe that it is necessary to form a provision for the likelihood of non-payment of its receivables owed by subsidiaries. For this reason the Company has not formed a provision against such receivables.

The outstanding balances of the accounts with related companies are as follows:

<u>Group (Substatartes)</u>				
	Company			
	Receivables	Liabilities	Income	Purchases
ATHENS MEDICAL S.A.	0	0	0	0
IATRIKI TECHNIKI	10	26.286	10	11.788
EREVNA S.A.	0	31	0	0
AXONIKI EREVNA S.A.	0	0	0	0
PHYSIOTHERAPY CENTRE	64	106	64	158
MEDSANA BUCHAREST MEDICAL CENTER	0	0	0	0
BIOAXIS SRL (ex MEDSANA SRL)	0	0	0	0
ORTELIA	1.686	0	0	0
EUROSITE	2.595	0	0	0
HOSPITAL AFFILLIATES INTERNATIONAL S.A.	327	0	0	0
TOTAL	4.682	26.423	73	11.946

More specifically, for the transactions mentioned above we clarify the following:

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The purchases of the Company mainly refer to purchases of medical materials from IATRIKI TECHNIKI S.A. transacted in the normal course of business. Liabilities exist due to this commercial relationship.

Other receivables from subsidiary companies are due to short term financial assistance towards those.

Company					
	Receivables from dividends	Income from dividends			
IATRIKI TECHNIKI	3.300	3.300			
PHYSIOTHERAPY CENTRE	66	66			
TOTAL	3.366	3.366			

	Group				Company			
	Receivables	Liabilities	Income	Purchases	Receivables	Liabilities	Income	Purchases
G. APOSTOLOPOULOS HOLDINGS	2	0	2	0	0	0	0	0
OIKODOMIKI EKMETALLEYTIKI E.A.E.	5	0	1	0	3	0	0	0
LA VIE ASSURANCE SYCHRONI	3.332	64	1.474	4	3.332	64	1.472	4
ECHODIAGNOSI	0	27	0	0	0	27	0	0
PROSTATE INSTITUTE	0	0	0	0	0	0	0	0
KORINTHIAKOS RYTHMOS	2	397	2	218	0	348	0	171
HERODIKOS	33	0	0	0	33	0	0	0
QUS	85	0	0	0	85	0	0	0
TRADOR S.A.	21	0	0	0	21	0	0	0
AGIOLOGIKI DIEREVNISI ATHENS PEDIATRIC	0	7	0	0	0	7	0	0
CENTER ILEKTRONISTAGMOGRAFI	15	0	0	0	15	0	0	0
KI	0	0	0	0	0	0	0	0
NEVROLITOURGIKI	0	0	0	0	0	0	0	0
MEDISOFT	190	0	0	0	190	0	0	0
MEDICAFE CATERING COMPANY S.A.	9	0	52	0	9	0	52	0
DOMINION – INSURANCE BROKERAGE S.A. INTEROPTIKS TRADING AND SERVICES OF PRINTED AND	0	30	0	14	0	30	0	14
ELECTRONIC INFORMATION SYSTEMS S.A. I.E. EUROHOSPITAL CONSULTING AND MANAGEMENT OF HOSPITALS S.A.	0	0	0	0	0	0	0	0
TOTAL	3.695	525	1.531	236	3.688	476	1.524	189

Other (Associates and other companies)

The income appearing in the above table refer mainly to the provision of hospitalisation services to customers of the insurance company LA VIE ASSURANCE. The receivables balance exists due to this commercial relationship. Liabilities refer mainly to rent obligations.

ATHENS MEDICAL CENTER S.A. A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008) (Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

	Group	•	Company		
	Receivables from dividends	Income from dividends	Receivables from dividends	Income from dividends	
MEDICAFE CATERING COMPANY S.A.	96	96	0	0	
	<u>Gro</u>	oup	<u>Company</u>		
Remuneration of executives and mer Management Remuneration of executives and mer Management from distribution of	mbers of the	<u>70</u>	3.245		
Management from distribution of	490 4.00		<u>200</u> <u>3.445</u>		
Receivables from executives and me Management		oup	Company		
Liabilities to executives and members of	10		-		
Liabilities to executives and members of	the Management 598	3	200		

Maroussi, 25 August 2008

THE BOARD OF DIRECTORS

A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008)

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Review Report of Interim Financial Information

To the Shareholders of «ATHENS MEDICAL CENTER S.A.»

Introduction

We have reviewed the accompanying condensed balance sheet of «ATHENS MEDICAL CENTER S.A.» («the Company»), the accompanying condensed consolidated balance sheet of the Company and its subsidiaries (the «Group») as of 30 June 2008 and the related condensed statements of income, changes in equity and cash flows of the Company and the Group for the six-month period then ended as well as the selected explanatory notes, that comprise the interim financial information, which is an integral part of the six-month financial report as required by article 5 of L. 3556/2007. Management is responsible for the preparation and presentation of this interim condensed financial information in accordance with International Financial Reporting Standards as adopted by the European Union and apply to interim financial information («IAS 34»). Our responsibility is to express a conclusion on this interim condensed financial information, based on our review.

Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements 2410 «Review of Interim Financial Information Performed by the Independent Auditor of the Entity», to which the Greek Auditing Standards refer. A review consists of making inquiries, mainly of persons responsible for accounting and financial matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Greek Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Consequently, the present document is not an audit report.

Conclusion on Review

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with IAS 34.

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Report on Other Legal and Regulatory Requirements

In addition to the interim financial information referred to above, we reviewed the remaining information included in the six-month financial report as required by article 5 of L.3556/2007 as well as the information required by the relevant Decisions of the Capital Market Commission as set out in the Law. Based on our review we concluded that the financial report includes the data and information that is required by the Law and the Decisions referred to above and is consistent with the accompanying financial information.

Athens, August 27, 2008

The Certified Auditor Accountant

George Gerasimou Vrettos
S.O.E.L. Registration Number 15651



(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)



ATHENS MEDICAL CENTER S.A.

INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED JUNE 30, 2008

IN ACCORDANCE WITH INTERNATIONAL FINANCIAL REPORTING STANDARDS (IFRS)

It is certified that the attached interim Financial Statements are those approved by the board of directors of "ATHENS MEDICAL CENTER S.A." in August 25th 2008 and they are uploaded to the internet address: www.iatriko.gr. The records and information published to the press aim at providing to the reader some general financial records and information, but they do not provide the whole picture of the financial condition and the results of the Company, according to the International Accounting Standards and the International Financial Reporting Standards.

Georgios Apostolopoulos President of the Board of Directors ATHENS MEDICAL CENTER S.A.

ATHENS MEDICAL CENTER S.A.

A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

CONTENTS OF INTERIM FINANCIAL STATEMENTS

	Page
Income Statement for the period ended June 30, 2008 and 2007	13
Balance Sheets as of June 30, 2008 and December 31, 2007	14
Statement of Changes in Equity for the period ended June 30, 2008	15
Statement of Changes in Equity for the period ended June 30, 2007	16
Cash Flow Statement for the the period ended June 30, 2008 and 2007	17
Corporate information	18
Preparation base of Financial Statements	18-19
Principal accounting policies	19-28
Risk management	29-30
Management's significant accounting judgements and estimates	31
Notes to the Financial Statements	32-50

A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008)

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

INCOME STATEMENT FOR THE PERIOD ENDED 30 JUNE 2008 AND 2007

The Company The Group 1/4-30/6 1/1-30/6 1/1-30/6 1/4-30/6 1/1-30/6 1/1-30/6 1/4-30/6 1/4-30/6 Notes 2007 2008 2007 2008 2007 2008 2007 INCOME: Revenue 148.078 150.224 73.870 72.230 144.687 147.218 72.184 70.804 Cost of sales (115.352)(115.099)(58.823) (56.235) (116.653) (59.378) (56.977) (116.466)**Gross Profit** 32.726 35.124 15.047 15.995 28.221 30.565 12.806 13.827 Administrative expenses and Distribution Costs (13.934)8 (15.744)(15.620)(8.767)(8.612)(13.935)(7.589)(7.528)Other income/ (expenses) 9 1.118 2.047 636 977 1.165 2.146 659 1.079 Net financial income/ (costs) 10 (4.547)(4.038)(1.778)(2.081)(998)345 909 1.278 PROFIT BEFORE TAX 13.552 17.514 5.138 6.279 14.453 19.122 6.786 8.657 Income Tax Expense 11 (3.656)(5.337)(1.644)(2.114)(2.967)(4.573) (1.296)(1.761)PROFIT FOR THE YEAR 9.896 12.176 3.494 4.164 11.485 14.549 5.490 6.896 Attributable to: Equity holders of the parent company 9.917 12.096 3.539 4.126 11.485 14.549 6.896 5.490 Minority Interest 80 (21) (45) 38 9.896 12.176 3.494 4.164 11.485 14.549 5.490 6.896 Earnings per Share (in Euro) Basic 12 0,11 0,14 0,04 0,05 0,13 0,17 0,06 0,08 Weighted average number of shares Basic 12 84.658.202 86.735.980 84.658.202 86.735.980 84.658.202 86.735.980 84.658.202

The accompanied notes and appendixes are inseparable part of the financial statements

ATHENS MEDICAL CENTER S.A.

A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

BALANCE SHEET OF 30 JUNE 2008 AND 31 DECEMBER 2007

		The G	Froup	The Company		
	Notes	30 June 2008	31 December 2007	30 June 2008	31 December 2007	
ASSETS	- 10000					
Non current assets :						
Property, plant and equipment	13	281.398	284.119	255.391	259.217	
Goodwill	14	1.979	1.979	-	-	
Intangible assets	14	363	340	340	312	
Investments in subsidiaries	15	_		34.867	34.867	
Investments in associates consolidated	13			31.007	31.007	
by the equity method	16	262	328	30	_	
Other long term debtors	10	382	377	378	370	
Deferred tax assets	11	5.360	5.121	5.318	5.067	
Total non current assets	11 .	289.744	292.263	296.324	299.834	
	•	209./44	292,203	290.324	299.034	
Current Assets:	1.7	6.600	(700	6.140	(422	
Inventories	17	6.600	6.789	6.148	6.432	
Trade accounts receivable	18	153.001	151.765	149.947	148.523	
Prepayments and other receivables	19	19.823	13.449	26.788	16.139	
Derivatives	20	1.338	-	1.338	-	
Financial assets at fair value through						
income statement		-	1	-	.	
Cash and cash equivalents	21	22.155	27.236	19.472	18.580	
Total current assets		202.917	199.240	203.693	189.674	
TOTAL ASSETS	•	492.661	491.503	500.017	489.508	
EQUITY AND LIABILITIES	:	472.001	471.505	300.017	407.500	
•						
Equity attributable to equity holders of						
the parent company	22	26,000	26,000	26.000	26,000	
Share capital	22	26.888	26.888	26.888	26.888	
Share premium	22	19.777	19.777	19.777	19.777	
Retained Earnings		49.336	44.629	59.043	52.761	
Legal, tax free and special reserves	23	75.999	75.994	75.464	75.464	
		172.001	167.289	181.172	174.891	
Minority Interest		377	398			
Total equity	_	172.378	167.687	181.172	174.891	
Non-current liabilities:	=	-	-	_		
Long term loans/borrowings	24	150.478	157.037	150.141	156.972	
Government Grants	25	10	10	9	9	
Deferred tax Liabilities	11	24.055	23.482	21.534	20.961	
Provision for retirement indemnities	26	14.867	13.849	14.765	13.745	
Other long term liabilities	20	5.081	5.477	4.325	4.506	
Total non-current liabilities	•	194.491	199.855	190.774	196.193	
	•	174.471	177.033	170.774	170.173	
Current liabilities:	27	07.576	01.722	07.740	02.046	
Trade accounts payable	27	87.576	91.722	97.742	92.946	
Ch	2.4	7.256	11 222	1.040	5.026	
Short term loans/borrowings	24	7.256	11.232	1.840	5.936	
Long term liabilities payable in the						
next year	24	-	-	<u>-</u>	-	
Current tax payable		8.946	6.360	7.438	5.257	
Derivatives	20	971		971		
Accrued and other current liabilities	28	21.044	14.647	20.080	14.285	
Total current liabilities		125.792	123.960	128.071	118.424	
TOTAL EQUITY AND LIABILITIES		492.661	491.503	500.017	489.508	
			24 27 14			

The accompanied notes and appendixes are inseparable part of the financial statements

A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008) (Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

STATEMENT OF CHANGES IN EQUITY 30 JUNE 2008

		Th	e Group				
						Minority	Total
	A1	tributable to equ	uity holders of the	parent company		Interest	Equity
			Legal,				
			Tax-free,				
	Share	Share	and special	Retained			
	capital	Premium	Reserves	earnings	Total		
Balance, 1 January 2008	26.888	19.777	75.994	44.629	167.289	398	167.687
Period's profits				9.917	9.917	(21)	9.896
Dividends				(5.204)	(5.204)		(5.204)
Attribution of profits to reserves			5	(5)	Ó		Ó
Exchange Differences			(1)		(1)		(1)
Balance, 30 June 2008	26.888	19.777	75.998	49.337	172.001	377	172.378
	TI. C	-	<u>-</u>	-	-		

The Company

	Share capital	Share Premium	Legal,, Tax-free, and special Reserves	Retained earnings	Total Equity
Balance, 1 January 2008	26.888	19.777	75.464	52.762	174.891
Period's profits				11.485	11.485
Dividends				(5.204)	(5.204)
Attribution of profits to reserves			0	(0)	(0)
Balance, 30 June 2008	26.888	19.777	75.464	59.043	181.172

The accompanied notes and appendixes are inseparable part of the financial statements

A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008) (Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

STATEMENT OF CHANGES IN EQUITY 30 JUNE 2007

		Th	e Group				
						Minority	Total
	A	ttributable to equ	uity holders of the	parent company		Interest	Equity
	Share capital	Share Premium	Legal, Tax-free, and special Reserves	Retained earnings	Total		
Balance, 1 January 2007	26.036	15.267	75.396	35.474	152.173	811	152.984
Issuance of Share Capital Period's profits Exchange Differences Attribution of profits to reserves Dividends of parent Dividends paid to minority Balance, 30 June 2007	26.888	4.510 19.777	(11) 28 75.413	12.096 0 (28) (5.204) 0 42.337	5.363 12.096 (11) 0 (5.204) 0 164.416	(459) 433	5.363 12.176 (11) (0) (5.204) (459) 164.849
	The Co	ompany					
	Share capital	Share Premium	Legal, Tax-free, and special Reserves	Retained earnings	Total Equity		
Balance, 1 January 2007	26.036	15.267	74.784	42.777	158.864		
Issuance of Share Capital	853	4.510	-	-	5.363		

The accompanied notes and appendixes are inseparable part of the financial statements

19.777

26.888

Period's profits

Balance, 30 June 2007

Dividends

74.784

14.549

(5.204)

52.122

14.549

(5.204)

173.571

ATHENS MEDICAL CENTER S.A.

A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

CASH FLOW STATEMENT FOR THE PERIOD ENDED JUNE 2008 AND 2007

	The Gr	oup	The Company		
_	30 June 2008	30 June 2007	30 June 2008	30 June 2007	
Cash flows from operating activities					
Period's profit before taxation	13.552	17.513	14.453	19.122	
Adjustments for operational activities					
Depreciation	5.795	5.491	5.503	5.266	
Depreciation of government grants	(0)	(0)	(0)	(0)	
Provision for retirement indemnities	1.019	949	1.019	944	
Allowance for doubtful accounts receivable	408	205	200	205	
(Gains)/losses due to fixed assets sale	3	(1.129)	3	(1.129)	
Dividends from subsidiaries	(96)	(91)	(3.366)	(4.351)	
(Gains) / losses from group's associates	97	(52)	0	(0)	
Interest and Financial income	(1.916)	(44)	(1.903)	(32)	
Interest and other financial expenses	6.462	4.216	6.266	4.037	
Exchange differences due to consolidation					
of subsidiaries abroad	(1)	(2)	0	0	
Operational profit before changes in					
working capital variations	25.323	27.056	22.175	24.062	
Increase/ (Decrease) in:					
Inventories	188	(324)	284	(307)	
Short and long term accounts receivable	(8.023)	(24.685)	(8.914)	(25.216)	
Increase/ (Decrease) in:					
Short and long term liabilities	(3.254)	10.786	5.206	13.884	
Interest charges and related expenses paid	(5.492)	(4.216)	(5.296)	(4.037)	
Paid taxes	(737)	(4.226)	(465)	(3.713)	
Net Cash from operating activities	8.006	4.391	12.990	4.673	
Cash flows from investing activities					
Purchase of tangible and intangible fixed					
assets	(3.102)	(4.144)	(1.709)	(3.967)	
Sale of tangible assets	2	11	2	11	
Interest and related income received	158	44	144	32	
Received dividends from subsidiaries	0	0	0	0	
Received dividends from other companies	0	0	0	0	
Guarantees paid	0	(1)	0	0	
Grants received	0	0	0	0	
Purchase of of long and short term					
investments	(30)	(0)	(30)	(0)	
Sale of of long and short term investments	421	(0)	420	(0)	
Net Cash flows used in investing activities	(2.551)	(4.090)	(1.173)	(3.924)	
Cash flows from financing activities	(21001)	(11050)	(11170)	(0.02.)	
Issuance of Shares	0	5.363	0	5.363	
Dividends paid of parent company	(0)	(2)	(0)	(2)	
Net variation of short term borrowings	(3.974)	7.648	(4.051)	7.059	
Net variation of of long term	(3.571)	7.010	(1.031)	7.007	
debt/borrowings	(6.162)	(11.381)	(6.475)	(11.251)	
Payment of finance lease liabilities	(400)	(1.316)	(400)	(1.316)	
Dividends paid to minority from	(400)	(1.510)	(400)	(1.510)	
subsidiaries	0	(459)	0	0	
-		•			
Net Cash flows used in financing activities	(10.536)	(147)	(10.926)	(147)	
Net increase/(decrease) in cash and cash					
equivalents	(5.081)	153	892	602	
Cash and cash equivalents at the beginning					
of the period	27.236	8.814	18.580	6.224	
Cash and cash equivalents at the end of the		_			
period	22.155	8.967	19.472	6.826	

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

2. CORPORATE INFORMATION:

The Company "ATHENS MEDICAL SOCIETE ANONYME" with the distinctive title "ATHENS MEDICAL CENTER S.A." (hereafter the "Company" or the "Parent Company") and its subsidiaries (hereafter the "Group") are involved in the area of health care services with the organization and operation of hospital units. The Company's and the Group's head offices are located in the Municipality of Amarousion Attica in 5-7 Distomou Street and employ 2.987 and 3.155 employees respectively.

The Company's shares are publicly traded on the Athens Stock Exchange.

The companies, which were included in the accompanying consolidated financial statements of the Group, together with the related ownership interests are described in table below:

Company's name	Company's location country	Activity	Participation (%)
IATRIKI TECHNIKI S.A.	GREECE	Sale of Medical Tools & Sanitary/Health Equipment	100,00%
EREVNA S.A.	GREECE	Diagnostic & Therapeutic Center	51,00%
AXONIKI EREVNA S.A.	GREECE	Diagnostic Center	50,50%
PHYSIOTHERAPY AND SPORTS INJURY TREATMENT CENTER S.A.	GREECE	Physiotherapy & Sport Injury Restoration/Treatment Services	33,00%
HOSPITAL AFFILIATES INTERNATIONAL	GREECE	Organization & Administration of Hospitals and Clinics.	68,89%
MEDSANA BMC	ROMANIA	Diagnostic Center	100,00%
BIOAXIS SRL (ex MEDSANA SRL)	ROMANIA	Diagnostic Center	78,90%
EUROSITE HEALTH SERVICES S.A.	GREECE	Establishment & Operation of Hospitals and Clinics	100,00%
ORTELIA HOLDINGS	CYPRUS	Establishment, Organization & Operation of Hospitals and Clinics	99,99%
MEDICAFE S.A.	GREECE	Pastry shop-buffet	55%
INTEROPTICS S.A.	GREECE	Trade & services of publication and electronic information & information systems	27,33%
I.E. EUROHOSPITAL S.A	GREECE	Management, Organization & Operation of Hospitals and Clinics	50,00%

3a. PREPARATION BASE OF FINANCIAL STATEMENTS:

(a) Basis of Preparation of the Consolidated Financial Statements: The accompanying consolidated financial statements that constitute the Group's consolidated financial statements (hereinafter referred to as "the financial statements") have been prepared in accordance with International Financial Reporting Standards ("IFRS"), adopted by the European Union. There are no standards applied in advance of their effective date. The financial statements have been prepared under the historical cost convention, except for derivative financial instruments which are measured at fair value.

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

- (b) Statutory Financial Statements: The Company and its domestic (Greek) subsidiaries maintain their accounting books and prepare financial statements in accordance to the Greek Company Law 2190/1920 and the applicable tax legislation. The foreign subsidiaries of the Company maintain their accounting records and prepare financial statements in accordance to the applicable laws and regulations of the countries in which they operate. For the preparation of the consolidated financial statements of the parent company, the financial statements of the foreign subsidiaries are adjusted in accordance to the provisions of the Greek Company Law 2190/1920. The accompanying consolidated financial statements have been based on the above-mentioned statutory consolidated financial statements appropriately adjusted and reclassified by certain out-of-book adjustments in order to comply with IFRS.
- (c) Approval of Financial Statements: The Board of Directors of Athens Medical S.A. approved the interim financial statements for the period ended in June 30th, 2008, in August 25, 2008.
- (d) Use of Estimates: The preparation of financial statements in conformity with the IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting year. Actual results may ultimately differ from those estimates.

3b. PRINCIPAL ACCOUNTING POLICIES

The principal accounting policies adopted in the preparation of the accompanying financial statements are the following:

(a) Basis of Consolidation: The Company's accompanying consolidated financial statements include the financial statements of the parent Company, as well as of all the subsidiaries that are controlled by the Parent Company. Control is presumed to exist when direct or indirect ownership retains the majority of voting interest or has the power to control the Subsidiaries' Board of Directors. Subsidiaries are consolidated from the date on which effective control is transferred to the company and cease to be consolidated from the date in which control ceases to exist.

The consolidated financial statements include the financial statements of a subsidiary (Physiotherapy Center S.A.), in which although the direct parent company holds less than 50% of the voting rights, controls it through the ability of appointing the majority of members of the Board of Directors.

In the consolidated financial statements, Medicafe S.A. is also included using the equity method, although, Group holds 55% of the company's voting rights, due to a management's transfer to third parties. As a result such ownership does not consist control according to IAS 27 « Consolidated and Separate Financial Statements », paragraph 13.

The Group's subsidiaries EREVNA S.A. and AXONIKI EREVNA S.A., according to their General Assemblies' decisions, have entered a liquidation procedure, since 1/7/2006. Before that and during the year 2006, the above mentioned companies have transferred together with all their productive assets – mechanical equipment, their operations to parent company and as a qonsequence their Balance Sheets do not include non current assets. As a result the liquidation of the above mentioned companies is not considered to be a discontinued operation according to IFRS 5 "Non-current Assets Held for Sale and Discontinued Operations", that requires distinctive reporting regarding the companies' results and fixed assets.

All intercompany transactions and balances have been eliminated in the accompanying consolidated financial statements. Where necessary, accounting policies of the subsidiaries have been revised to ensure consistency with the policies adopted by the Group.

(b) Investments in Subsidiaries (separate financial statements): The investments of the parent Company in its consolidated subsidiaries are measured at acquisition cost less any cumulative impairment losses.

(c) Investments in Associates:

- i) Consolidated financial statements: The Company's investments in other entities in which parent exercises significant influence and are not subsidiaries or joint-ventures are accounted for using the equity method. Under this method the investment in associates is recognized at cost in addition to the changes in the percentage of the Company in the associate's equity after the initial date of acquisition less possible provisions for impairment in value. The consolidated statement of income reflects the Company's share of the results of operations of the associate.
- ii) Separate financial statements of parent: Investments in associates in the stand-alone financial statements are measured at acquisition cost less any cumulative impairment losses.

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

(d) Conversion of foreign currencies: The base currency of the Company and of its Greek subsidiaries is Euro. The transactions involving other currencies are converted into Euro using the exchange rates that were in effect at the time of the transactions. At the balance sheet date monetary assets and liabilities which are denominated in other currencies are adjusted in order to reflect the current exchange rates.

Gains and losses resulting from year end FX adjustments of monetary assets and liabilities are reflected in the accompanying income statement. Gains and losses resulting from transactions are reflected in the accompanying statement of income also.

The base currency of the Group's foreign subsidiaries is the official currency of the related country in which each subsidiary operates. Thereafter, at each reporting date all balance sheet accounts of these subsidiaries are converted into Euro using the exchange rate in effect at the balance sheet date. Revenues and expenses are converted based on the weighted average rate of exchange that prevailed during the year.

The accumulated difference resulting from such translation is recognized directly in consolidated equity until the disposal, write off or de-recognition of a subsidiary, when it is transferred to the consolidated income statement.

- (e) Intangible Assets: Intangible assets are mainly consisted of software and commercial rights. These are amortized over their estimated useful lives which are set to five years.
- (f) Research and Product Development Cost: Research costs are expensed as incurred. Development expenditure is mainly incurred for the development of new products. Costs incurred for the development of an individual project are recognized as an intangible asset only when the requirements of IAS 38 "Intangible Assets" are met.
- (g) Revenue recognition: Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. The following particular recognition criteria must also be met as revenue is recognized.

Sale of Services

The Sale of Services revenue is accounted according to the extent of service completion.

Sale of goods

The sale of goods revenue, net of trade discounts sale, incentives and the related VAT, is recognized when the significant risks and rewards of ownership of the goods have passed to the buyer.

Interests

The interest revenue is recognized on the accrual basis of accounting.

Dividends

Revenue from dividends is recognized when the Group's right on such dividends is approved by the respective bodies of the companies' that declare them.

(j) Property, Plant and Equipment: Land and buildings are valued at historical cost (deemed cost based on the provisions of IFRS 1), less accumulated depreciation and any impairment in value. Machinery, transportation equipment, as well as the furniture and the rest of the equipment are measured at historical cost less the accumulated depreciation and any impairment in value.

The Company and the Group proceeded to a fair valuation of its land, buildings, as at January 1, 2004 and these fair values were used as deemed cost on the date of transition to the IFRS. The resulted revaluation surplus was credited to retained earnings.

Repairs and maintenance are charged to expenses as incurred. Major improvements are capitalized to the cost of the asset to which they relate when they extend the useful life, increase the earnings capacity or improve the efficiency of the respective assets.

An item of property and plant is derecognized upon sale or disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on derecognition of the asset, is included in the consolidated statement of income in the year the item is derecognized.

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

(ja) Depreciation: Depreciation is calculated based on the straight-line method at rates, which approximately reflect the average useful lives of relative assets. The rates used are the following:

Classification	Annual rate
Buildings	2%
Machinery and Equipment	6,67%- 10%
Equipment of Transportation	6%-10%
Furniture and rest of Equipment	10%- 20%

(jc) Goodwill: Business combinations are accounted for using the acquisition accounting method. This involves recognizing identifiable assets (including previously unrecognized intangible assets) and liabilities (including contingent liabilities) of the acquired business at fair value. Goodwill acquired in a business combination is initially measured at cost being the excess of the cost of the business combination over the Group's interest in the net fair value of the acquiree's identifiable assets, liabilities and contingent liabilities. Following initial recognition, goodwill is measured at cost less any accumulated impairment losses.

Goodwill is not amortized, but it is reviewed for impairment, annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired. At the acquisition date (or at the date of completion of the relative purchase price allocation) any goodwill acquired is allocated to each of the cash-generating units related to goodwill.

Impairment is determined by assessing the recoverable amount of the cash-generating unit, to which the goodwill relates. Where the recoverable amount of the cash-generating unit is less than the carrying amount and the relevant goodwill, an impairment loss is recognized.

Where goodwill forms part of a cash-generating unit and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on disposal of the operation. Goodwill disposed of, in this circumstance is measured on the basis of the relative values of the operation disposed of and the portion of the cash-generating unit retained.

Goodwill resulting from acquisitions or business combinations has been allocated to the main cash generating units in group level. The cash generating units have been defined in accordance with the provisions of IAS 36 "Impairment of Assets". The Group, in order to decide whether an impairment of goodwill exists, performed the related impairment tests in the cash generating units in which goodwill was allocated, and based on those tests no impairment issue occurred.

When the Group increases its participation interest to existing subsidiaries (acquisition of minority interests) the total difference between the purchase price and the portion of the minority interests acquired (goodwill or negative goodwill) is transferred directly to equity as it is considered as a transaction among the shareholders (entity concept method). Similarly, when minority interests are sold (without losing control of the subsidiary) then the related gains or losses are recognized directly to equity.

(jd) Impairment of Assets: With the exception of goodwill and intangibles with indefinite life, which are reviewed for impairment at least annually, the carrying value of other non-current assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Whenever the carrying value of an asset exceeds its recoverable amount a respective impairment loss is recognized in the consolidated statement of income. The recoverable amount is measured as the higher of net selling price and value in use. Net selling price is the amount obtainable from the sale of an asset in an arm's length transaction between knowledgeable, willing parties, after deducting any direct incremental selling costs, while value in use is the present value of estimated future cash flows expected to arise from continuing use of the asset and from the revenue due to its disposal at the end of its estimated useful life. For the purpose of assessing impairment, assets are grouped at the lowest level for which there are separately identifiable cash flows.

(je) De-recognition of Financial Assets and Liabilities

- (i) Financial assets: A financial asset (or, where applicable a part of a financial asset or part of a group of similar financial assets) is derecognized when:
- the rights to receive cash flows from the asset have expired;
- the Group retains the right to receive cash flows from the asset, but has assumed an obligation to pay them in full without material delay to a third party under a "pass-through" arrangement; or

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

- the Group has transferred its rights to receive cash flows from the asset and either (a) has transferred substantially all the risks and rewards of the assets, or (b) has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset. Where the Group has transferred its rights to receive cash flows from an asset and has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the asset is recognized to the extent of the Group's continuing involvement in the asset. Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay. Where continuing involvement takes the form of a written and/or purchase option (including a cash-settled option or similar provision) on the transferred asset, the extent of the Group's continuing involvement is the amount of the transferred asset that the Group may repurchase, except that in the case of a written put option (including a cash-settled option or similar provision) on an asset measured at fair value, where the extent of the Group's continuing involvement is limited to the lower of the fair value of the transferred asset and the option exercise price.
- (ii) Financial liabilities: A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. Where an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a de-recognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognized in profit or loss.
- (jf) Inventories: Inventories are reported at the lower value between the cost and the net realizable value. Cost of finished and semi-finished products includes all costs incurred in bringing inventories to their current location and state of manufacture and comprises raw materials, labour, an applicable amount of production overhead (based on normal operating capacity, but excluding borrowing costs) and packaging. The cost of raw materials and finished goods is determined based on the weighted average basis. Net realizable value for finished goods is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary, to make the sale. The net realizable value for raw materials is the estimated replacement cost in the ordinary course of business. Especially medication supply are measured in a different way, that is at the last acquisition value, due to existing state of tariff, according to I.A.S. 2 (inventories), paragraph 25.
- (jh) Accounts Receivable and Credit Policy: Short-term receivables are presented at their nominal value, net of provisions for potential non collectible accounts, while long-term receivables (balances that deviate from normal credit terms) are reported at the amortized cost based on the actual interest rate method. At each Balance sheet date all past due or doubtfull debtors are assessed by management in order to determine the necessity for relevant provision, with criteria such as the customer's ability to pay and the aging of his balance. The balance of such allowance for doubtful accounts is appropriately adjusted at each balance sheet date in order to reflect all possible risks. Any amount written—off with respect to customer account balances is charged against the existing allowance for doubtful accounts. It is the Group's policy not to write-off an account until all possible legal action has been exhausted.
- (jg) Credit Risk Concentration: The major part of debtors comes from public insurance organizations and private insurance companies, whose credit risk is considered to be limited. Regarding the rest of debtors, represented by sale to individuals, risk is diversified due to the great diversity of balances.
- (k) Cash and Cash Equivalents: The Company considers time deposits and other highly liquid investments with original maturity of three months or less, to be cash equivalents. For the purpose of the cash flow statements, cash and cash equivalents consist of cash at hand and in banks and of cash and cash equivalents as defined above.
- (ka) Share capital: Share capital represents the value of the Parent company's shares issued and in circulation. Any excess of the fair value of the consideration received over the par value of the shares issued is recognized as the "share premium" in shareholders equity. Incremental external costs directly attributable to the issue of new shares are shown as a deduction in equity, net of tax, from the proceeds.
- (kb) Long-term Liabilities: All long-term liabilities are initially recognized at cost. After initial recognition loans and borrowings denominated in foreign currency are reported using the spot rate at each reporting date. The interest costs are recognized on the accrual basis of accounting.
- (kc) Borrowing Costs: Borrowing Costs are recognized as an expense in the period in which they are incurred.
- (kd) Provision for Retirement Indemnities: Staff Retirement obligations are calculated at the discounted value of the future retirement benefits deemed to have accrued at year-end, based on the employees earning retirement benefit rights throughout the expected working period. Retirement obligations mentioned above are calculated on the basis of financial and actuarial assumptions and are determined using the Projected Unit credit actuarial valuation Method. Net pension costs for the period are included in

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

payroll in the accompanying income statement and consist of the present value of benefits earned in the year, interest cost on the benefit obligation, past service cost, actuarial gains or losses and any additional pension charges. Past service costs are recognized on a straight-line basis over the average period until the benefits under the plan become vested.

Unrecognized actuarial gains or losses are recognized over the average remaining service period of active employees and included as a component of net pension cost for a year if, as of the beginning of the year, it exceeds 10% of the future projected benefit obligation. The retirement benefit obligations are not funded.

(*ke*) *State Pension:* The Company's personnel is covered by several State sponsored pension funds for private sector employees, (I.K.A., T.S.A.Y.) covering post-retirement pensions, and healthcare benefits. Each employee is required to contribute a portion of its monthly salary to the fund, with the company also contributing a portion. Upon retirement, the pension fund is responsible for paying the employees retirement benefits. At such, the company has no legal or constructive obligation to pay future benefits under this plan.

(aa) Borrowings: All borrowings are initially recognized at acquisition cost, which reflects the fair value of amounts collected, net of any relevant transaction costs incurred. After initial recognition, they are measured at amortised cost, based on the effective interest rate. Gains or losses arising from differences of amortised cost are \Box oreseeabl in the income statement, as well as differences due to the de-recognition (repayment) of the borrowings. Borrowing costs are \Box oreseeabl as expenses in the period incurred.

(ab) Income Taxes (Current and Deferred): Current and deferred income taxes are computed based on the stand alone financial statements of each of the entities included in the consolidated financial statements, in accordance with the tax rules in force in Greece or other tax jurisdictions in which foreign subsidiaries operate. Income tax expense is computed based on each entity's profits as adjusted in its tax returns, additional income taxes resulting from tax audits by the tax authorities and deferred income taxes, using substantively enacted tax rates.

Deferred income tax is computed, using the liability method, on all temporary differences at the balance sheet date between the tax bases and the carrying amounts of assets and liabilities. Deferred income tax liabilities are recognized for all taxable temporary differences:

- Except cases, where the deferred income tax liability arises from goodwill impairment or the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss, and
- In respect of taxable temporary differences associated with investments in subsidiaries, associates and interest in joint ventures, except where the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the \Box oreseeable future.
- Deferred tax assets are recognized for all discounted temporary differences and transferred tax assets and losses, to the extent where it is possible that taxable profit will be available which will be used against the discounted temporary differences and the transferred unused taxable assets and losses.
- Except cases where the deferred tax asset regarding the discounted temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss and
- In respect of taxable temporary differences associated with investments in subsidiaries, associates and interest in joint ventures, an income deferred tax is recognized to the extent that it is probable that the temporary differences will reverse in the foreseeable future and there will be available taxable profit which will be used against temporary differences.

The deferred tax assets are reviewed at each balance sheet date and reduced to the extent, where it is not considered as possible that enough taxable profits will be presented against which, a part or the total deferred tax assets can be utilized.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on the tax rates (and the laws) that have been enacted or substantively enacted at the balance sheet date.

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The income tax relating to items recognized directly in equity, is recognized in equity and not in the income statement.

(ac) Financial Leases: Finance leases, which transfer to the Company substantially all the risks and benefits incidental to ownership of the leased item, are capitalized at the inception of the lease at the fair value of the leased property or, if lower, at the present value of the minimum lease payments. Lease payments are apportioned between the finance charges and the reduction of the lease liability so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are charged directly to income. Capitalized leased assets are depreciated over estimated useful life of the asset or the lease term.

Leases where the lessor retains substantially all the risks and benefits of ownership of the asset are classified as operating leases. Operating lease payments are recognized as an expense in the income statement on the straight line basis over the lease term.

- (ad) Provisions and Contingencies: Provisions are recognized when the Company has a present legal or presumed/imputed obligation as a result of past events, it is probable that an outflow of resources will be required to settle this obligation and a reliable estimate of the amount of the obligation can be made. Provisions are reviewed at each balance sheet date and adjusted to reflect the present value of the expenditure expected to be required to settle the obligation. If the effect of time value of money is material, provisions are determined by discounting the expected future cash flows at a pretax rate that reflects current market assessments of the time value of money and, where appropriate the risks specific to the liability. Contingent liabilities are not recognized in the consolidated financial statements but they are disclosed unless the possibility of an outflow of resources embodying economic benefits is remote. Contingent assets are not recognized in the financial statements but are disclosed when an inflow of economic benefits is probable.
- (ae) Earnings per share: Basic earnings per share are computed by dividing net income attributed to the Group's shareholders by the weighted average number of ordinary shares outstanding during each year, excluding any treasury shares outstanding during the year. Diluted earnings per share are computed by dividing net income attributed to the Group's shareholders (after deducting the impact on the convertible recognized preference shares) by the weighted average number of ordinary shares outstanding during the year (after deducting the impact on the convertible recognized preference shares).
- (af) Segment reporting: The group has one segment, the health care services. It is also involved mainly in the Greek territory and its activities abroad do not have sufficient extend in order to consist a segment. Consequently, the presentation of relevant financial information is not necessary.
- (ba) Derivative Financial Instruments and hedging activities: Derivatives are initially recognized at fair value on the date a derivative contract is entered into and are subsequently measured at their fair value. The method of recognizing the resulting gain or loss depends on whether the derivative is designated as a hedging instrument, and if so, the nature of the item being hedged. The Group documents, at the inception of the transaction, the relationship between hedging instruments and hedged items, as well as its risk management objectives and strategy for undertaking various hedging transactions. The Group also documents its assessment, both at hedge inception and on an ongoing basis, of whether derivatives that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items.

In February 2008, the Group has entered financial intrument contracts and more specifically, simple interest rate swaps, or interest rate collars designated as cash flow hedges. These contracts were joined due to obligations deriving from the Common Bond Loan contract, issued by the Group in July and November of 2007. According to the Common Bond Loan contract's provisions, the Group would proceed in financial instrument agreements, which would limit interest rate risk exposure, at least for half of the Common Bond Loan amount. The financial instrument contracts the Group has entered correspond with precision to the dates of interest expense charge and capital repayment of the Common Bond Loan.

The effective portion of changes in the fair value of these derivatives is recognized in equity. The gain or loss relating to the ineffective portion is recognized immediatelly in the income statement. Amounts accumulated in equity are recycled in the income statement in the periods when the hedged item affects profit or loss (when the forecast transaction being hedged takes place).

The derivatives that are not designated as hedges and do not qualify for hedge accounting are classified as held-for-trading and accounted for at fair value through profit or loss.

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

(bb) Investments and other (non derivative) financial assets:

Financial assets in the scope of IAS 39 are classified as either

- financial assets at fair value through profit or loss,
- loans and receivables,
- held-to-maturity investments,
- available-for-sale financial assets, as appropriate.

When financial assets are recognized initially, they are measured at fair value, plus, directly attributable transaction costs.

The Group determines the classification of its financial assets after initial recognition and, where allowed and appropriate, re-evaluates this designation periodically.

(i) Financial assets at fair value through profit or loss:

Financial assets are classified as held for trading if they are acquired for the purpose of selling in the near term. Gains or losses on investments held for trading are recognized in income.

(ii) Loans and receivables:

Such assets, derived by the company's activity (that is beyond the Group's ordinary credit limits), are carried at amortised cost using the effective interest method. Gains and losses are recognized in the income statement when the loans and receivables are de-recognized or impaired, as well as through the amortization process.

(iii) Held-to-maturity investments:

Non-derivative financial assets with fixed or determinable payments and fixed maturity are classified as held-to-maturity when the Group has the positive intention and ability to hold to maturity. Investments intended to be held for an undefined period are not included in this classification. Other long-term investments that are intended to be held-to-maturity, after initial recognition are subsequently measured at amortised cost, using the effective interest method. For investments carried at amortised cost, gains and losses are recognized in income when the investments are de-recognized or impaired, as well as through the amortization process.

(iv) Available-for-sale financial assets:

Available-for-sale financial assets are those non-derivative financial assets that are designated as available-for sale or are not classified in any of the three preceding categories. After initial recognition available-for sale financial assets are measured at fair value with gains or losses being recognized as a separate component of equity until the investment is sold, de-recognized or until the investment is determined to be impaired at which time the cumulative gain or loss previously reported in equity is included in the income statement.

The fair value of investments that are actively traded in organized financial markets is determined by reference to quoted market bid prices at the close of business on the balance sheet date. For investments where there is no active market, fair value is determined using valuation techniques. Such techniques include using recent arm's length market transactions; reference to the current market value of another instrument, which is substantially the same; discounted cash flow analysis and option pricing models.

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

(bc) New Standards and Interpretations, amendments of valid Standards: The International Accounting Standards Board, as well as the IFRIC, have already issued a number of new accounting standards and interpretations or have amended valid standards, whose application is mandatory for the periods beginning January 1, 2008 onwards (except if mentioned otherwise below). The Group's and company's management's assessment regarding the effect of these new standards and interpretations is as follows:

IFRS 7 Financial Instruments: Disclosures and supplementary adjustment in IAS 1 Presentation of Financial Statements (valid since January 1, 2007):

IFRS 7 introduces added disclosures in order to improve the incoming information relating to the financial instruments. It requires the disclosure of quality and quantity information regarding the risk exposure due to financial instruments. More specifically it defines minimum required discosures relating to credit risk, cash flow risk as well as market risk (imposes the sensitivity analysis concerning the market risk). IFRS 7 replaces the IAS 30 (Disclosures in the Financial Statements of banks and similar Financial Institutions) and the disclosure requirements of IAS 32, (Financial Instruments: disclosureς and presentation). It is applicable in all entities that prepare financial statements according to IFRS. The adjustment to IAS 1 introduces disclosures relating the amount of entities' capital as well as its management. The group and the company has assessed the effect of IFRS 7 and the adjustment of IAS 1 and came to the conclusion that the additional disclosure required by their application is the sensitivity analysis regarding the market risk and the capital disclosures. The group will apply IFRS 7 and the amendment of IAS 1 from January 1, 2007.

IFRS 4 Insurance contracts:

(valid since January 1, 2007) IFRS 4 is not applicable in Group's operations.

IFRS 8 Operating Segments:

(valid since January 1, 2009)

IFRS 8 replaces IAS 14 (Segment Reporting) and adopts a management approach to segment reporting. The information reported would be that which management uses internally for evaluating the performance of operating segments and for allocating resources to those segments. This information may be different from that reported in the balance sheet and income statement and entities will need to provide expanations and reconciliations of potential differences. The Group is in a procedure of studying the above mentioned standard, which will be applied by the Group from January 1, 2009.

IAS 23 (Amendment) Borrowing cost: (valid since January 1, 2009)

In the revised IAS 23 (Borrowing cost), the previous benchmark treatment of recognizing borrowing costs as an expense has been eliminated. Instead, borrowing costs that are directly attributable to the acquisistion, construction or production of qualifying assets form part of the costs of the asset. The Group is in a procedure of studying the above mentioned standard.

IFRIC 7: Applying the restatement approach under IAS 29 financial reporting hyperinflationary economies (valid since March 1, 2006):

IFRIC 7 requires entities to apply IAS 29 (Financial reporting in hyperinflationary economies) in the reporting period in which an entity first identifies the existence of hyperinflation in the economy of its functional currency, as if the economy had always been hyperinflationary. IFRIC 7 is not applicable for the Group.

IFRIC 8: Scope of IFRS 2 (valid since May 1, 2006):

IFRIC 8 clarifies that IFRS 2 (Share based payments) will apply to any arrangement when equity instruments are granted or liabilities (based on the value of an entity's equity instrument) are incurred by an entity, when the identifiable consideration appear to be less than the fair value of the instruments given or the liabilities incurred. Is not applicable for the Group and will not affect the financial statements.

IFRIC 9: Remeasurment of embedded derivatives (valid since June 1, 2006):

IFRIC 9 requires an entity to assess whether a contract contains an embedded derivative at the date an entity first becomes a party to the contract and prohibits reassessment unless there is a change to the contract that significantly modifies the cash flows. Is not applicable for the Group and will not affect the financial statements.

IFRIC 10: Interim financial reporting and impairment (valid since November 1, 2006):

This interpretation requires the non reversal of impairment recognized in interim reporting due to goodwill or an investment in an equity instrument, or an asset carried at cost. Consequently such impairment can not be reversed in future interim or annual financial statements. The Group will apply this interpretation after January 1, 2007.

IFRIC 11: IFRS 2 Group and treasury Share transactions (valid since March 1, 2007): IFRIC 11 refers to issues relating to IFRS 2 and specifically to compensations that are determined by the value of company's own shares and personell salaries of a subsidiary that are determined by the shares of the parent company. Is not applicable for the Group and will not affect the financial statements.

A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008)

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

IFRIC 12, Service Concession Arrangements: (valid since 1 January 2008)

IFRIC 12 outlines an approach to account for contractual arrangements arising from entities providing public services. It provides for the operator should not account for the infrastructure as property, plant and equipment, but recognize a financial asset and / or an intangible asset. IFRIC 12, which is expected to be adopted by the EU in the near future, is not relevant to the Group's operations.

IFRIC 13. Customer Loyalty Programmes:(Valid since 1 July 2008)

IFRIC 13 clarifies that where entities grant award credits (e.g. points) as apart of a sale transaction and customers can redeem those award credits in the future for free or discounted goods or services. IAS 18 paragraph 13 applies. This requires that the award credits are treated as a separate component of the sales transaction and an amount of the consideration received or receivable needs to be allocated to the award credits. The timing of the recognition of this element of revenue is deferred until the entity satisfies its obligations relating to the award credits, either by supplying the rewards directly or by transferring the obligation to a third party. Is not applicable for the Group and will not affect the financial statements.

IFRIC 14. I.A.S. 19 The limit on a Defined Benefit Asset, Minimum Funding Requirements and their interaction (Valid since 1 January 2008)

IFRIC 14 provides guidance on how to assess the limit in IAS 19 (Employee Benefits) on the amount of the surplus that can be recognised as an asset. It also explains how the pension asset or liability may be affected when there is a statutory or contractual minimum funding requirement. The Group is in a procedure of studying the above mentioned interpretation, which will be applied by the Group from January 1, 2008.

IFRIC 15. Agreements for the construction of real estate (Valid since 1 January 2009)

The interpretation will standardise accounting practise across juristictions for the recognition of revenue among real estate developers for sales of units, such as apartments or houses, "off plan", before contruction is complete. Is not applicable for the Group and will not affect the financial statements.

IFRIC 16. Hedges of a Net Investment in a Foreign operation (Valid since 1 October 2008)

The interpretation provides guidance on accounting for the hedge of a net investment in a foreign operation in an entity's consolidated financial statements. The Group is in a procedure of studying the above mentioned interpretation.

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

(bd) Comparative figures: Profit before taxes, financing and investing activity and profit before taxes, financing, investing activity and depreciation of Group and Company, for the period 1/1-30/6/2007 have been reformed for purposes of decision 34/24.1.2008 of Capital Market's Board of Directors Commission as following:

	Gro	oup	Company		
	1/1-30/6/2007	1/4-30/6/2007	1/1-30/6/2007	1/4-30/6/2007	
Profit before taxes	17.513	6.278	19.122	8.657	
Plus					
Net financial (income)/ costs					
(Income Statement)	<u>4.038</u>	<u>2.081</u>	(345)	(1.278)	
Profit before taxes, financing and					
investing activity					
(as published in the respective period					
of 2007)	21.552	8.359	18.777	7.378	
Less					
(Gains)/losses due to fixed assets					
sale					
(Cash flow statement)	(1.129)	(566)	(1.129)	(566)	
Losses from exchange differences					
related to subsidiary Iatriki Tehniki					
(Financial income/costs Note 10)	<u>(10)</u>	<u>1</u>	<u>-</u>	=	
Profit before taxes, financing and					
investing activity					
(as published in the respective period					
of 2008)	20.413	7.795	17.648	6.813	

And

	Gro	oup	Company	
	1/1-30/6/2007	1/4-30/6/2007	1/1-30/6/2007	1/4-30/6/2007
Profit before taxes	17.513	6.278	19.122	8.657
Plus				
Net financial (income)/ costs				
(Income Statement)	4.038	2.081	(345)	(1.278)
Depreciation				
(Cash flow statement)	<u>5.491</u>	<u>2.758</u>	<u>5.266</u>	<u>2.633</u>
Profit before taxes, financing,				
investing activity and				
depreciation (as published in the				
respective period of 2007)	27.043	11.118	24.043	10.012
Less				
(Gains)/losses due to fixed assets				
sale				
(Cash flow statement)	(1.129)	(566)	(1.129)	(566)
Losses from exchange differences				
related to subsidiary Iatriki Tehniki				
(Financial income/costs Note 10)	<u>(10)</u>	<u>1</u>	-	Ξ
Profit before taxes, financing,			_	
investing activity and				
depreciation (as published in the				
respective period of 2008)				
	25.904	10.553	22.914	9.446

The above reform had no effect a) Revenue, b) profit after tax and non controlling interests c) equity attributable to equity holders of the parent company, for company and group of period 1/1-30/6/2007.

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

4. RISK MANAGEMENT

The Group's main financial instruments are cash and cash equivalents, bank deposits (sight and time), trade accounts receivable, prepayments and other receivables and accounts payable, bank loans (borrowings) and financial assets at fair value through income statement. Management periodically evaluates and revises the policies and procedures that relate to management of financial risk, which are described below:

a) Market risk

(i) Foreign exchange translation risk (FX translation risk)

The Group holds participations (business operations) in Romania, whose net assets are exposed to FX translation risk. This kind of FX translation risk derives from the exchang rate RON/€ and it is not hedged as there is no substantial exposure.

(ii) Price risk

The Group is not exposed to securities price risk due to its non investment in entities and their classification in the consolidated balance sheet as financial assets at fair value through income statement.

(ii) Cash flow and fair value interest rate risk

The Group has no significant interest – bearing assets, so the group's income and operating cash flows are substantially independent of changes in market interest rates. The Group's interest rate risks arises from long – term borrowings. Borrowings issued at variable rates expose the group to cash flow interest rate risk.

For diminishing the effect of the above mentioned interest rate risk beginning from year 2008 Group entered financial contracts for interest rate risk hedging purposes.

The Group policy is to minimize its exposure to interest rate cash flows risk with regard to long term financing issued at variable rates

b) Credit risk

Credit risk arises from cash and cash equivalents, deposits with banks and financial institutions, as well as credit exposures to customers, including outstanding receivables and committed transactions. Risk control department assesses the credit quality of the customer, taking into account its financial position, past experience and other factors. Trade debtors credit limits are set based on internal ratings in accordance with limits set by management.

The major part of debtors comes from public insurance organizations and private insurance companies, whose credit risk is considered to be limited. Regarding the rest of debtors, represented by sale to individuals, risk is diversified due to the great diversity of balances.

Regarding prepayments and other receivables as well as cash and cash equivalents credit risk is considered of no significance.

c) Liquidity risk

Prudent liquidity risk management implies maintaining sufficient cash and cash equivalents, the availability of funding through an adequate amount of committed credit facilities. Furthermore, the Group has entered into factoring, aiming to support its working capital.

The following table depict's Group's and Company's financial liabilities classified in groups by the time period, estimated from the date of balance sheet to the date payable.

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Group at 30.6.2008

Group at 30.6.2008			
	Less than 1 year	Between 1 and 5 years	Over 5 years
Borrowings Trade accounts	7.256	31.133	119.345
payable and other liabilities	117.566	5.081	
Total	124.822	36.214	119.345
Group at 31.12.2007			
	Less than 1 year	Between 1 and 5	Over 5 years
		years	
Borrowings Trade accounts payable and other	11.232	26.985	130.052
liabilities	112.729	5.477	
Total	123.961	32.462	130.052
Company at 30.6.2008			
	Less than 1 year	Between 1 and 5	Over 5 years
Borrowings Trade accounts	1.840	years 30.796	119.345
payable and other liabilities	125.260	4.325	
Total	127.100	35.121	119.345
Company at 31.12.2007			
- •	Less than 1 year	Between 1 and 5	Over 5 years
Domovvings	5.936	years	130.052
Borrowings Trade accounts	5.930	26.919	130.032
payable and other liabilities	112.488	4.506	
	440.444		4.0.0.

d) Capital management policies and procedures

The Group's objectives when managing capital are to safeguard the Group's ability to continue as going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

31.425

130.052

118.424

e) Fair value estimation

Total

The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques based on market conditions existing at each balance sheet date. Other techniques, such as estimated discounted cash flows, are used to determine fair value for the remaining financial instruments. The nominal value less estimated credit adjustments of trade receivables is assumed to approximate their fair values.

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

5. MANAGEMENT'S SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES

The Group proceeds to judgments and estimates in order to apply the most representative accounting methods and policies or in connection with the future development of transactions and events. Such judgments and estimates are periodically reviewed by management in order to reflect current condition and correspond to anticipation of current risks and are based on prior Management's experience in conjunction to the volume / level of such transactions and events.

The principle judgments and estimates referring to events the development of which could significantly affect the items of the financial statements during the forthcoming twelve months period are as follows:

Significant accounting estimates and relative uncertainty:

i) Goodwill impairment test

The Group determines whether goodwill is impaired at least on an annual basis. This requires an estimation of the value in use of the cash-generating units to which the goodwill is allocated. Estimating the value in use requires the Group to make an estimate of the expected future cash flows from the cash-generating unit and also to choose a suitable discount rate in order to calculate the present value of those cash flows.

As it is explained in note 14 of the financial statements, the goodwill arose from the purchase of minority's percentage of Group's subsidiary's "IATRIKI TEHNIKI S.A." that took place in the second semester of year 2005. Management has received two valuation reports from two independent appraisals regarding the business value of "IATRIKI TEHNIKI S.A.", which are based in its estimated future cash flows. Considering the significant profitability of "IATRIKI TEHNIKI S.A." assessed by the company's results of years 2005, 2006, 2007 and the first semester of year 2008. also greater by the estimations of valuations, management trusts that the company's operational profits will maintain in the near future and there is no reason for excercising impairment loss.

ii) Provisions for income taxes

Income (current) tax liabilities according to IAS 12 for the current and prior periods are measured at the amounts expected to be paid to the taxation authorities, using the tax rates that have been enacted by the balance sheet date. (Provision for income taxes reported in the respective income tax returns and the potential additional tax assessments that may be imposed by the tax authorities upon settlement of the open tax years). Accordingly, the financial settlement of the income taxes might differ from the income taxes that have been accounted for in the financial statements. Further details are provided in Note 11.

A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008) (Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

6. PAYROLL COST:

The Payroll cost that is included in the accompanying financial statements is analyzed as follows:

	The Group		The Co	mpany
	30/6/2008	30/6/2007	30/6/2008	30/6/2007
Wages and Salaries	34.166	30.259	33.225	29.347
Social security costs	8.457	7.162	8.218	6.930
Compensations and Provision for retirement				
indemnities	1.136	1.019	1.133	1.014
Other staff expenses, management fees	2.146	2.052	1.795	1.574
Total payroll	45.905	40.492	44.371	38.865
Less: amounts charged to cost of sales	(35.249)	(30.737)	(34.794)	(30.282)
Payroll expensed to administrative and				
distribution cost (Note 8)	10.656	9.755	9.577	8.583

7. DEPRECIATION AND AMORTISATION:

Depreciation and amortization accounted in the accompanying financial statements is analyzed as follows:

	The Group		The Company	
	30/6/2008	30/6/2007	30/6/2008	30/6/2007
Depreciation of property land and equipment				
(Note 13)	5.741	5.478	5.462	5.253
Amortization of intangible assets (Note 14)	54	13	42	13
	5.795	5.491	5.504	5.266
Less: depreciation and amortization charged				
to cost of sales	(5.356)	(4.967)	(5.129)	(4.876)
Depreciation and amortization expensed to administration and distribution cost				
(Note 8)	439	524	375	390

8. ADMINISTRATIVE EXPENSES AND DISTRIBUTION COSTS:

The administrative expenses and distribution costs that are presented in the accompanying financial statements are analyzed as follows:

	The Group		The Cor	npany
	30/6/2008	30/6/2007	30/6/2008	30/6/2007
Payroll cost (Note 6)	10.656	9.755	9.577	8.583
Third party fees	841	713	703	648
Depreciation and amortization (Note 7)	439	524	375	390
Third party services	1.092	1.520	930	1.347
Provision for impairment	408	205	200	205
Other expenses	2.308	2.903	2.150	2.761
Total	15.744	15.620	13.935	13.934

ATHENS MEDICAL CENTER S.A. A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008) (Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

9. OTHER INCOME / (EXPENSES):

The other income / (expenses) that are presented in the accompanying financial statements are analyzed as follows:

	The Group		The Company	
	30/6/2008	30/6/2007	30/6/2008	30/6/2007
Income from rentals/other services	748	638	800	737
Government Grants, special tax returns	42	23	42	23
Other Income	289	250	289	250
Profit on disposals of fixed assets	(3)	1.136	(3)	1.136
Income from prior years	42		37	
Total	1.118	2.047	1.165	2.146

10. FINANCIAL INCOME/(COSTS):

The financial income/ (costs) that are presented in the accompanying financial statements are analyzed as follows:

The Group	30/6/2008	<u>30/6/2007</u>
Interest on non-current loans/borrowings	(4.183)	(1.593)
Interest on current loans/borrowings & relevant expenses	(649)	(1.981)
Factoring commissions	(97)	(260)
Finance lease interest	(563)	(376)
Derivative valuation	(970)	· -
Losses from exchange differences	0	(15)
Total financial costs	(6.462)	(4.225)
Gains/(losses) from associates	(97)	53
Dividends from investments in companies and from shares	96	91
Interest on deposits	158	43
Gain due to derivative sale	420	-
Derivative valuation	1.338	-
Gains from exchange differences	0	-
Total financial income	1.915	187
Financial income/(costs)	(4.547)	(4.038)

The company	30/6/2008	30/6/2007
Interest on non-current loans/borrowings	(4.182)	(1.590)
Interest on current loans/borrowings & relevant expenses	(464)	(1.816)
Factoring commissions	(97)	(260)
Derivative valuation	(970)	-
Finance lease interest	(553)	(372)
Total financial costs	(6.266)	(4.038)
Interest on deposits	144	32
Gain due to derivative sale	420	-
Derivative valuation	1.338	-
Dividends from investments in companies and from shares	3.366	4.351
Total financial income	5.268	4.383
Financial income/(costs)	(998)	345

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

11. INCOME TAXES:

According to the tax legislation, the tax rate applicable in companies for the year of 2008 is 25%. (25 % until the 31st of December 2007).

The provision for income taxes presented in the accompanying financial statements is analyzed as follows:

	The Group		The Company	
	30/6/2008	30/6/2007	30/6/2008	30/6/2007
Current income taxes:				
Current income tax charge	3.331	3.605	2.645	2.890
Prior years' taxes	(9)	672	0	654
Deferred income taxes	334	1.060	322	1.029
Total provision for income taxes	3.656	5.337	2.967	4.573

Greek tax laws and related regulations are subject to interpretations by the tax authorities. Tax returns are filed annually but the profits or losses declared for tax purposes remain provisional until such time, as the tax authorities examine the returns and the records of the taxpayer and a final assessment is issued. Tax losses, to the extent accepted by the tax authorities, can be used to offset profits of the five fiscal years following the fiscal year to which they relate.

Regarding its subsidiaries, the tax authorities have not audited their books and their elements for the years mentioned in table below:.

Company's name	Company's location country	Activity	Participation (%)	Tax audited years
IATRIKI TECHNIKI S.A.	GREECE	Sale of Medical Tools & Sanitary/Health Equipment	100,00%	2007
EREVNA S.A.	GREECE	Diagnostic & Therapeutic Center	51,00%	2007
AXONIKI EREVNA S.A.	GREECE	Diagnostic Center	50,50%	2007
PHYSIOTHERAPY AND SPORTS INJURY TREATMENT CENTER S.A.	GREECE	Physiotherapy & Sport Injury Restoration/Treatment Services	33,00%	2007
HOSPITAL AFFILIATES INTERNATIONAL	GREECE	Organization & Administration of Hospitals and Clinics.	68,89%	2001-2007
MEDSANA BMC	ROMANIA	Diagnostic Center	100,00%	1997-2007
BIOAXIS SRL (ex MEDSANA SRL)	ROMANIA	Diagnostic Center	78,90%	1997-2007
EUROSITE HEALTH SERVICES S.A.	GREECE	Establishment & Operation of Hospitals and Clinics	100,00%	2003-2007
ORTELIA HOLDINGS	CYPRUS	Establishment, Organization & Operation of Hospitals and Clinics	99,99%	1998-2007
MEDICAFE S.A.	GREECE	Pastry shop-buffet	55%	2003-2007
INTEROPTICS S.A.	GREECE	Trade & services of publication and electronic information & information systems	27,33%	2005-2007
I.E. EUROHOSPITAL S.A.	GREECE	Management, Organization & Operation of Hospitals and Clinics	50,00%	

In a future tax audit of the related unaudited years, additional taxes and penalties may be assessed to the Company and to its subsidiaries. The Company regards that the outcome of the tax audits and the amount of the possible added taxes and fines, is possible to estimate and, thus, a relevant provision has been made in the consolidated financial statements related to this subject, amounted to ϵ 490 thousand.

ATHENS MEDICAL CENTER S.A. A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008) (Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The deferred income taxes related to the temporary differences between the book values and the tax bases of assets and liabilities are calculated using the applicable statutory income tax rate.

	The Group	The Company
Opening balance, January 1 st 2008	(18.362)	(15.894)
Charged directly to equity		
Charged to the statement of income	(334)	(322)
Closing balance, June, 30st 2008	(18.695)	(16.216)
	The Group	The Company
Opening balance, January 1 st 2007	(15.994)	(13.566)
Charged directly to equity		
Charged to the statement of income	(2.368)	(2.328)
Closing balance, December, 31st 2007	(18.362)	(15.894)

	The G	roup_	The Company		
	30 st June	31 st December	30 st June	31 st December	
Deferred income tax Liabilities	<u>2008</u>	<u>2007</u>	<u>2008</u>	<u>2007</u>	
- Property plant and equipment	(21.207)	(20.503)	(18.685)	(17.982)	
- Leases	(2.403)	(2.629)	(2.403)	(2.629)	
- Other	(445)	(350)	(445)	(350)	
_	(24.055)	(23.482)	(21.534)	(20.961)	
Deferred income tax Assets					
- Accounts receivable	765	715	765	715	
- Deferred expenses	923	989	907	961	
- Leases	0	0	0		
- Provision for retirement indemnities	3.717	3.463	3.691	3.437	
- Other	(46)	(46)	(46)	(46)	
Deferred income tax Assets	5.360	5.121	5.318	5.067	
Net deferred income tax Liabilities	(18.695)	(18.362)	(16.216)	(15.894)	

The effect of the deferred taxes in debits/(credits) of the income statement is the following:

	The G	roup	The Company		
	30 st	31 st	30 st	31 st	
	<u>June</u>	December	<u>June</u>	December	
	2008	2007	2008	2007	
Deferred income tax Liabilities			<u> </u>		
- Property plant and equipment	(704)	(1.426)	(703)	(1.405)	
- Leases	226	(42)	226	(42)	
- Other	(95)	(157)	(95)	(161)	
	(573)	(1.625)	(572)	(1.608)	
Deferred income tax Assets	, , ,	, , ,		, ,	
- Accounts receivable	50	(84)	50	(84)	
- Deferred expenses	(66)	(594)	(54)	(568)	
- Leases	0	(564)	0	(564)	
- Provision for retirement indemnities	255	500	255	496	
- Other	0	0	0	0	
	239	(742)	251	(720)	
(Debit)/Credit of deferred income tax	(334)	(2.368)	(322)	(2.328)	

ATHENS MEDICAL CENTER S.A. A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008) (Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

12. EARNINGS PER SHARE:

The calculation of basic earnings per share in the 30th of June 2008 and 2007 is the following:

	The Group		The Company	
	30 st June	30 st June	<u>30st</u> June	30 st June
	<u>2008</u>	<u>2007</u>	2008	<u>2007</u>
Net profit attributable to equity holders of the				
parent	9.917	12.096	11.485	14.549
Weighted average number of shares				
outstanding	86.735.980	84.658.202	86.735.980	84.658.202
Basic earnings per share				
Net profit per share attributable to equity				
holders of the parent	0,11	0,14	0,13	0,17

13. PROPERTY PLANT AND EQUIPMENT:

Property, plant and equipment is analyzed as follows:

Movement for A' semester of 2008 - Group

	Land	Buildings and installation s	and	Transporta tion equipment	Furniture and fixtures	Constructio n / Purchases in Progress	Total
Cost or measurement						<u> </u>	
Balance 1.1.2008	67.880	177.388	65.914	2.487	28.752	8.622	351.043
Exchange Differences	4	1					5
Additions		120	1.167	130	393	1.215	3.025
Sales/Deletions		(99)	(8)				(107)
Impairment							
Transitions and							
reclassifications			4		(6)		(2)
Balance 30.6.2008	67.884	177.410	67.077	2.617	29.138	9.837	353.964
Depreciation							
Balance 1.1.2008		(12.960)	(32.302)	(1.778)	(19.885)		(66.924)
Exchange Differences		(5)	3	(3)			(5)
Year's Additions		(1.777)	(2.811)	(89)	(1.064)		(5.741)
Sales/Deletions		99	4				103
Transitions and							
reclassifications			(4)		6		2
Period total		(1.683)	(2.808)	(92)	(1.058)		(5.641)
Balance 30.6.2008		(14.644)	(35.110)	(1.870)	(20.942)		(72.566)
Net Book Value							
30.6.2008	67.884	162.766	31.966	747	8.197	9.837	281.398

Movement for year 2007 – Group

	Land	Buildings and installation	Machinery and equipment	Transporta tion equipment	Furniture and fixtures	Constructio n / Purchases in Progress	Total
Cost or measurement	65.303	s 163.721	61.082	2.575	27.242	19.796	339.720
Balance 1.1.2007							
Exchange Differences	(4)	(44)	(72)	(4)	(8)	(1)	(134)
Additions	38	1.386	4.345		1.542	2.041	9.352
Sales/Deletions			(148)	(83)	(24)		(255)
Transitions and							
reclassifications	2.543						2.543
Transfers from fixed		12 225	707			(12.214)	(102)
assets under constructions		12.325	707			(13.214)	(182)
Balance 31.12.2007	67.880	177.388	65.914	2.487	28.752	8.622	351.043
Danwaiatian							
Depreciation Balance 1.1.2007		(9.558)	(27.148)	(1.649)	(17.588)		(55.943)
Exchange Differences		6	31	2	2		42
Year's Additions		(3.408)	(5.280)	(195)	(2.319)		(11.202)
Sales/Deletions			95	63	20		179
Period total		(3.402)	(5.154)	(130)	(2.297)		(10.982)
Balance 31.12.2007		(12.960)	(32.302)	(1.778)	(19.885)		(66.924)
Net Book Value 31.12.2007	67.880	164.428	33.612	709	8.868	8.622	284.119

Movement for A' semester of 2008 - Company

	Land	Buildings and installations	Machinery and equipment	Transportat ion equipment	Furniture and fixtures	Constructio n / Purchases in Progress	Total
Cost or measurement							·
Balance 1.1.2008	51.308	175.351	60.916	2.168	28.008	5.695	323.446
Additions		120	801	72	384	262	1.639
Sales -Deletions			(8)				(8)
Transitions and reclassifications			4		(6)		(2)
Balance 30.6.2008	51.308	175.472	61.713	2.240	28.386	5.957	325.075
Depreciation							
Balance 1.1.2008		(12.606)	(30.561)	(1.644)	(19.418)		(64.229)
Year's Additions		(1.761)	(2.603)	(63)	(1.035)		(5.462)
Sales -Deletions			3		1		4
Transitions and reclassifications			(4)		7		3
Period Total		(1.761)	(2.604)	(63)	(1.027)		(5.455)
Balance 30.6.2008		(14.367)	(33.165)	(1.707)	(20.445)		(69.684)
Net Book Value		(14.507)	(33.103)	(1.707)	(20.773)		(07.004)
30.6.2008	51.308	161.105	28.548	533	7.940	5.957	255.391

Movement for year 2007 - Company

	Land	Buildings and installation s	Machinery and equipment	Transporta tion equipment	Furniture and fixtures	Constructio n / Purchases in Progress	Total
Cost or measurement	48.727	161.640	57.097	2.248	26.501	16.147	312.361
Balance 1.1.2007							
Additions	38	1.386	4.074		1.521	1.922	8.942
Sales -Deletions			(255)	(80)	(14)		(350)
Transitions and reclassifications Transfers from fixed	2.543						2.543
assets under constructions		12.325				(12.374)	(50)
Balance 31.12.2007	51.308	175.351	60.916	2.168	28.008	5.695	323.446
Depreciation							
Balance 1.1.2007		(9.317)	(25.742)	(1.558)	(17.168)		(53.785)
Year's Additions		(3.288)	(4.973)	(147)	(2.261)		(10.668)
Sales/Deletions			154	60	10		224
Period total		(3.288)	(4.819)	(87)	(2.251)		(10.444)
Balance 31.12.2007		(12.606)	(30.561)	(1.644)	(19.418)		64.229
Net Book Value 31.12.2007	51.308	162.745	30.355	524	8.590	5.695	259.217

There are no restrictions on title or transfer or other encumbrances on the Group's land and buildings. In addition, no item of land, building and machinery equipment has been pledged as security for liabilities.

14. INTANGIBLE ASSETS

The Group

Cost	Goodwill	Rights/Licenses	Other	Total
Balance 1.1.2008	1.979	66	879	2.923
Additions			77	77
Deletions			(22)	(22)
Balance 30.6.2008	1.979	66	934	2.978
Accumulated amortization Balance 1.1.2008			(605)	(605)
Additions			(54)	(54)
Deletions			22	22
Balance 30.6.2008	-		(637)	(637)
Net Book Value 30.6.2008	1.979	66	297	2.342

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

_	Goodwill	Rights/Licenses	Other	Total
Cost				_
Balance 1.1.2007	1.979	398	659	3.035
Additions		2.211	220	2.431
Reclassifications		(2.543)		(2.543)
Balance 31.12.2007	1.979	66	879	2.923
Accumulated amortization				
Balance 1.1.2007			(549)	(549)
Additions			(56)	(56)
Balance 31.12.2007			(605)	(605)
Net Book Value 31.12.2007	1.979	66	274	2.318

The goodwill amounted to € 1.979 thous resulted from the acquisition of a further 5% of the subsidiary's share capital IATRIKI TECHNIKI S.A., a company that is operating in Greece in the sector of medical and surgical instrument production and trading, as well as of all kinds of sanitary/health equipment. The buying-out of the further 5% that was typically completed in the third quarter of 2005, has been recognized according to the buy-out method and represents the difference between the paid up price and the fair value of the assets that were purchased as they were valuated at the respective transaction dates. From the progress of activities until now, no indications have arisen showing that the possibility of an impairment test must be examined.

The group in the b' six month period of 2006 acquired the rest 44% percentage and now owns 100% of the subsidiary's Iatriki Tehniki Share Capital. The amount required, for the acquisition of the 44%, of \in 21.282 thous, was not recognized as additional goodwill due to purchase method, but it reduced equally the consolidated Equity, as it arose from subsidiary purchase in which the group had already control.

The Company

The Company	Rights/Licenses	Other	Total
Cost			
Balance 1.1.2008	66	812	878
Additions		70	70
Balance 30.6.2008	66	882	948
Accumulated amortization			
Balance 1.1.2008		(566)	(566)
Additions		(42)	(42)
Balance 30.6.2008		(608)	(608)
Net Book Value 30.6.2008	66	274	340
	Rights/Licenses	Other	Total
Cost	•		
Balance 1.1.2007	398	636	1.034
Additions	2.211	176	2.387
Reclassifications	(2.543)		(2.543)
Balance 31.12.2007	66	812	878
Accumulated amortization			
Balance 1.1.2007		(527)	(527)
Additions		(39)	(39)
Balance 31.12.2007		(566)	(566)
Net Book Value 31.12.2007	66	246	312

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

15. INVESTMENTS OF PARENT COMPANY IN SUBSIDIARIES

The investments of the Company in subsidiaries at the 30th June 2008 are analyzed as follows:

	Participation	Acquisition cost
Iatriki Techniki S.A.	100,00%	25.421
Physiotherapy center S.A	33,00%	19
Axoniki Erevna S.A.	50,50%	545
Erevna S.A	51,00%	503
Hospital Affiliates International	68,89%	91
Eurosite S.A	100,00%	8.335
Ortelia Holdings	99,99%	1.039
Medsana Buch	100,00%	33
BIOAXIS SRL (ex Medsana Srl)	78,90%	517
Athens Paediatrics Center	58,30%	169
		36.672
Impairment loss		(1.805)
Balance		34.867

The above-mentioned subsidiaries are consolidated, except from Athens Pediatrics Center SA, which is under liquidation procedure and its acquisition cost is totally deleted in the Company's retained earnings. The operation of this company was interrupted before the transition date, the assets and liabilities of its balance sheets are of minor significance and the liquidation procedure does not entail significant costs for the Company. Until the reporting date of the accompanying financial statements no final judicial decision has been issued for its dissolution and its final deletion from the S.A. register, in contradiction to the Prostate Institute and Electronystagmografiki S.A., which according to relative decisions of their residences' Prefectures have been deleted from the S.A. register. The acquisition costs of Prostate Institute and Electronystagmografiki S.A. were totally deleted in the Company's retained earnings and as a result their deletion from the company's financial statements had no effect in previous year's 2006 results.

The acquisition cost in Ortelia Holdings SA and in BIOAXIS SRL (ex Medsana Srl) has been completely deleted in the stand alone financial statements of the Company, according to the provisions of **IAS 27** and **38**. These companies, do not present any operation and their accounting value is greater of their recoverable amount. At the transition date in IFRS, an impairment test took place in the above mentioned investments, during which, it was attributed in Company's cash generating units. The recoverable amount, which in this case was the value of use, was lower than the carrying amount and the impairment loss arose and amounted to € 1.805 thous, was charged against the retained earnings of 1st of January 2004.

16. INVESTMENTS IN ASSOCIATES CONSOLIDATED BY THE EQUITY METHOD

These concern Company's investments in the capital share of the following companies in a percentage between 20% and 50% and in which no important influence is exercised.

The Company

	Percentage	Acquisition cost
Medisoft S.A.	45,00%	132
Interoptics S.A.(ex-In Health S.A.)	27,33%	340
Aggiologiki Dierevnisi Ltd	20,00%	2
Herodikos Ltd	20,00%	19
I.E. Eurohospital S.A.	50,00%	30
		523
Impairment loss		(493)
Net carrying amount	_	30

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The carrying amount of the above companies is deleted in the Company's Equity at a time prior the transition date and the same classification is preserved since the 1st January 2004. The same goes with Nevrolitourgiki S.A., which according to a relevant decision of its residences' Prefecture has been deleted from the S.A. register. Due to the deletion of its acquisition cost to the company's retained earnings, its deletion from the company's financial statements had no effect in previous year's 2006 results.

It is noted that company In Health S.A. was merged through absorbtion from company Interoptics S.A. at 15 March 2005 and as a result group obtains a percentage of 27,33% on the capital of Interoptics S.A. instead of 30,37% that was obtained on the capital of the absorbed company In Health S.A. Management for the preparation of the financial statements of period 1/1-30/6/2008, did not reverse the impairment loss recognised on the acquisition cost of the investment on Interoptics S.A. .(ex-In Health S.A.) in the company's stand alone financial statements, according to **IAS 39** § 66, but included it in its consolidated financial statements using the equity method according to **IAS 28**.

In the first semester of year 2008 company I.E. EUROHOSPITAL S.A. was formed, in which ATHENS MEDICAL CENTER S.A. and EUROMEDICA S.A. participate with a percentage of 50% each. The company's residence is Athens and its purpose is management, organization and operation of Hospitals and Clinics.

The Group

(Percentage in equity -indirect participation- at 31/12/2007)	328
Formation of I.E. EUROHOSPITAL S.A.	30
Gain from associates - Interoptics S.A., Medicafe S.A., I.E. Eurohospital S.A.	(97)
Total	262

The total amount of loss from associates of \in 97 thousand has been included in the financial income (Note 10).

17. INVENTORIES:

The inventories are analyzed as follows:

	The Group		The Company	
	<u>30/6/2008</u>	31/12/2007	30/6/2008	31/12/2007
Merchandise	59	19		
Raw materials and consumable materials	6.496	6.725	6.148	6.432
Finished and semi-finished products	45	45		
	6.600	6.789	6.148	6.432

18. TRADE ACCOUNTS RECEIVABLE:

The trade accounts receivable are analyzed as follows:

	The Group		The Company	
	30/6/2008	31/12/2007	30/6/2008	31/12/2007
Trade debtors – open balances	136.217	136.224	135.535	135.538
Checks receivable (postdated) & bills				
receivable	19.376	17.641	17.011	15.300
Past due debtors	495	579	280	364
Less: Provision for impairment (trade debtors)	(3.087)	(2.679)	(2.879)	(2.679)
_	153.001	151.765	149.947	148.523

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

19. PREPAYMENTS AND OTHER RECEIVABLES:

The prepayments and other receviables are analyzed as follows:

	The Group		The Company	
	30/6/2008	31/12/2007	30/6/2008	31/12/2007
Advance payments for purchases	3	18	0	3
Advances to third parties	814	439	744	438
Other accounts receivable	12.011	10.906	11.105	9.909
Short-term receivables from associates	15	15	7.939	4.038
Prepaid expenses and other debtors	6.980	2.071	7.000	1.751
	19.823	13.449	26,788	16.139

20. DERIVATIVES:

	The G <u>Asso</u> <u>Fair v</u>	ets	The Cor <u>Asso</u> <u>Fair v</u>	<u>ets</u>
The second second	<u>30/6/2008</u>	<u>31/12/2007</u>	<u>30/6/2008</u>	31/12/2007
Interst rate Derivatives				
(Contacts' nominal value 50.000.000 euros)	1.338	-	1.338	
	1.338		1.338	
	The G	roup	The Cor	npany
	Total Equity a	nd liabilities	Total Equity a	nd liabilities
	<u>Fair v</u>	<u>alue</u>	Fair v	alue
	30/6/2008	31/12/2007	30/6/2008	31/12/2007
Interst rate Derivatives		·		
(Contacts' nominal value 100.000.000 euros)	971	-	971	-
	971		971	

The derivatives' fair value is based on market to market assessment. For all swap contracts, fair values are confirmed from financial institutions with which the group has entered relevant contracts.

21. CASH AND CASH EQUIVALENTS:

The cash and cash equivalents are analyzed as follows:

	The G	The Group		The Group The Company		npany
	<u>30/6/2008</u>	31/12/2007	30/6/2008	31/12/2007		
Cash in hand	744	531	684	501		
Deposits (sight and time)	21.411	26.705	18.788	18.079		
	22.155	27.236	19.472	18.580		

The bank deposits are lent at interest with floating interest rates based on the monthly interest rates of bank deposits. The income from sight and time bank deposits interest is recognized in accrual basis of accounting.

22. SHARE CAPITAL:

The share capital of the Company in 30^{th} June 2008, consists of 86.735.980 common nominal shares, with nominal value \in 0,31 each.

The Company's shares are publicly traded on the Athens Stock Exchange (main market).

According to the Shareholders Record of the Company, in the 30th of June 2008, the shareholders with a holding a percentage in the Company greater than 2 % were the following:

ATHENS MEDICAL CENTER S.A.

A' SIX MONTH FINANCIAL REPORT (1st January 2008 to 30th June 2008)

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

	Number of shares acquired	30 th June 2008
G. Apostolopoulos Holdings S.A.	27.833.843	32,09%
Asklepios International Gmbh	26.649.532	30,73%
2S Banca Milano	2.418.127	2,79%
Morgan Stanley and Co International PLC	5.903.583	6,81%
Pygar master fund (Cayman) Ltd	2.372.500	2,74%
Free float <2%	21.558.395	24,84%
	86.735.980	100,00%

The share premium of the Company resulted from the period of 1991 until the period of 2002, with a total amount of \in 15.267, by the issuing of shares against cash, in value greater than their nominal value. After the Share Caital increase according to the 1st and 18th December 2006, decisions of the Extraordinary and A' Repeated Extraordinary General Assembly of Stockholders, share premium of the Company at 30th June 2008 comes up to \in 19.777 thousand.

23. LEGAL, TAX FREE AND SPECIAL RESERVES:

The legal, tax free and special reserves are analyzed as follows:

The Group

	<u>30/6/2008</u>	31/12/2007
Legal reserve	4.988	4.983
Tax free and specially taxed reserves	70.649	70.649
Other	362	362
	75.999	75.994

The Company

	<u>30/6/2008</u>	31/12/2007
Legal reserve	4.476	4.476
Tax free and specially taxed reserves	70.548	70.548
Other	440	440
	75,464	75.464

Legal Reserve: According to the Greek Company law, the companies are obliged to form at least 5% of their annual net profits, as they are represented in the accounting books, in legal reserve, until the accumulated amount of the legal reserve reaches at least the 1/3 of the capital share. The above-mentioned reserve cannot be distributed during the operation of the Company.

Tax free and Specially Taxed Reserves: The untaxed and specially taxed reserves represent interest income, which are tax free or taxed by 10% at their source. The particular income is not taxable under the condition that adequate profits exist, from which respective untaxed reserves can be formed. According to the Greek tax legislation, this reserve is excluded from income tax, under the condition that it will not be distributed to the shareholders. The Company does not intend to distribute the particular reserve and thus it has not proceeded to the estimation of deferred income tax that would have been necessary in the case of reserve distribution.

Special Reserves: The special reserves have been formed based on the decisions of the shareholders' General Assemblies. The Company does not intend to distribute the particular reserves.

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

24. LOANS:

	The Group		The Group The Company		npany
Non-current loans	30/6/2008	31/12/2007	30/6/2008	31/12/2007	
Common bond loan	149.345	149.365	149.345	149.357	
Finance leases	1.133	7.672	796	7.615	
	150.478	157.037	150.141	156.972	
Current loans					
Bank loans	5.293	5.250			
Non-current loans payable within the next 12					
months	-	-	-	-	
Finance leases	801	1.179	678	1.133	
Other loans (factoring)	1.162	4.803	1.162	4.803	
	7.256	11.232	1.840	5.936	
Total of loans due	157.734	168.269	151.981	162.908	

	The Group		The Company	
Maturity of non-current loans	30/6/2008	31/12/2007	30/6/2008	31/12/2007
Between 1 & 2 years		8		
Between 2 & 5 years	30.000	24.000	30.000	24.000
Over 5 years	119.345	125.357	119.345	125.357
	149.345	149.365	149.345	149.357

The Group's borrowing mainly concerns the Common Bond Loan, with initial amount of \in 149.357 thous. , (Amount of borrowing \in 120.000 thous. plus \in 30.000 thous. in the last quarter of year 2007, minus transaction costs directly attributable to loan acquisition in accordance to **I.A.S. 39** § 43), according to the Common Bond Loan issuance contract from the 24/5/2007, with the Bank "ALPHA BANK" as a manager and lender Banks the following: **NATIONAL BANK of GREECE, EFG EUROBANK ERGASIAS** and **ALPHA BANK**. According to the contract, the purpose of this loan was the refunding of existing borrowing as well as the funding of company's general purposes. The loan's duration is eight years. The loan's repayment in full, will be conducted in 11 six-month installments. The first installment will be deposited in 19/7/2010, after a three year of grace and the final installment will be deposited in 19/7/2015. The interests concerning the above-mentioned loan are estimated according to the six month Euribor interest rate plus a margin, which will be defined according to a financial ratio of "**Net borrowings to EBITDA**" on a consolidated basis, and will be between 1,15% (valid) and 1,50%.

The current bank loans are received by the Company and its subsidiaries for serving their needs in working capital.

The loan cost has charged the year's results according to accrual basis principle.

The liabilities that result from leases concern the leasing mechanical – hospital equipment. The liabilities to the lessor are analyzed as follows:

Leasing Liabilities - Minimum payments of leases:

	The Group		The Company	
	30/6/2008	31/12/2007	30/6/2008	31/12/2007
Up to one year	876	1.614	733	1.564
Between 1 & 5 years	1.213	4.247	823	4.185
After 5 years	0	5.146	0	5.146
Total	2.089	11.007	1.556	10.895
Future finance charges on finance leases	(155)	(2.156)	(81)	(2.147)
Present value of lease liability	1.934	8.851	1.475	8.747

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The present value of the leasing liabilities is the following:

	The G	The Group		mpany
	30/6/2008	31/12/2007	30/6/2008	31/12/2007
Until one year	801	1.179	678	1.133
From 1 to 5 years	1.133	2.977	797	2.919
After 5 years		4.695	-	4.695
	1.934	8.851	1.475	8.747

Over the leased assets ownership retention exists, which will stay in force until the ending of the leasing period and the payment in full of the leases.

There are no other guaranties and commitments of ownership or use over the fixed assets and the other assets of the Group.

25. GOVERNMENT GRANTS:

The movement in the government grants during the period ended in 30th June 2008 and the year ended in 31st December 2007 was the following:

	The Group	The Company
Balance 1.1.2008	10	9
Additions	-	-
Depreciation		<u>-</u>
Balance 30.6.2008	10	9
	The Group	The Company
Balance 1.1.2007	36	35
Additions	5	5
Depreciation	(31)	(31)
Balance 31.12.2007	10	9

26. PROVISION FOR RETIREMENT INDEMNITIES:

- (a) Government Insurance Programs: The contributions of the Company and the Group to the insurance funds for the period ended in 30th June 2008, were recognized as expenses and amounted to \in 8.218 thousand and \in 8.457 thousand respectively.
- (b) Provision for retirement indemnities: According to the Greek employment legislation, the employees entitled to receive compensation in case of dismissal or retirement, the amount of which varies depending on the salary, the years of service and the type of retirement (dismissal or pensioning) of the employee. Employees that resign or get dismissed with a justification are not entitled to receive compensation. The payable compensation in case of retirement equals the 40% of the compensation that would have been payable in case of an unjustified dismissal. In Greece, according to the local practice, these programs are not granted. The Company debits to the results for the accrued benefits in every period with a relevant rise of the pensioning liability. The payments of the benefits performed to the pensioners every period are charged against this liability.

The movement of the net liability in the accompanying balance sheets of the Company and the Group is the following:

The Company	30 th June	31st December	
	2008	2007	
Net liability at the beginning of the year	13.745	11.759	
Actual benefits paid by the Company	(113)	(180)	
Expense recognized in the income statement (Note 6)	1.133	2.166	
Net liability at the end of the year	14.765	13.745	

The Group	30 th June	31st December
Net liability at the beginning of the year	<u>2008</u> 13.849	<u>2007</u> 11.847
Actual benefits paid by the Company	(118)	(246)
Expense recognized in the income statement (Note 6)	1.136	2.248
Net liability at the end of the year	14.867	13.849

An international firm of independent analogists/actuaries evaluated the Company's liabilities arising from the obligation to pay retirement indemnities.

The details and principal assumptions of the actuarial study as at 30th of June 2008 and 31st of December 2007 is the following:

739 333 64	16.632 (2.783) 13.849 1.472 514 124	736 333	16.528 (2.783) 13.745 1.391 514
333 64	13.849 1.472 514	,	13.745 1.391
333 64	1.472 514	,	1.391
333 64	514	,	-107
333 64	514	,	-107
64	*	333	514
	124		J 1 T
		64	124
1.136	2.110	1.133	2.028
	138		138
1.136	2.248	1.133	2.166
13.849	11.847	13.745	11.759
739	1.472	736	1.391
333	514	333	514
(118)	(246)	(113)	(180)
	138		138
64	124	64	124
14.867	13.849	14.765	13.745
1	6_		2007 4.8% 4.2% 2.5%
	13.849 739 333 (118) 64 14.867	1.136 2.110 138 1.136 2.248 13.849 11.847 739 1.472 333 514 (118) (246) 138 64 124	64 124 64 1.136 2.110 1.133 138 1.136 2.248 1.133 13.849 11.847 13.745 739 1.472 736 333 514 333 (118) (246) (113) 138 64 124 64 14.867 13.849 14.765

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The additional cost of extra benefits relates to benefits paid to employees, who became redundant. Most of these benefits were not expected within the terms of this plan and accordingly, the excess of benefit payments over existing reserves have been treated as an additional pension charge.

27. TRADE ACCOUNTS PAYABLE:

The trade accounts payable are analyzed as follows:

	The G	roup	The Company		
	30/6/2008	31/12/2007	30/6/2008	31/12/2007	
Suppliers	74.673	75.416	86.297	86.297	
Checks outstanding and bills payable					
(postdated)	12.903	16.306	11.445	11.445	
	87.576	91.722	97.742	97.742	

28. ACCRUED AND OTHER CURRENT LIABILITIES:

The amount represented in the accompanying consolidated balance sheet is analyzed as follows:

	The G	<u>roup</u>	The Company		
	30/6/2008	31/12/2007	30/6/2008	31/12/2007	
Customers' advances	-	-	-	-	
Obligations to associates	34	34	34	34	
Sundry creditors	5.644	4.034	5.137	3.861	
Cheques payable	-	1.328	-	1.328	
Insurance and pension contributions payable	3.485	4.204	3.425	4.126	
Accrued expenses	4.366	3.458	4.218	3.365	
Dividends	5.244	40	5.244	40	
Other	2.271	1.549	2.022	1.531	
	21.044	14.647	20.080	14.285	

29. RELATED PARTY DISCLOSURES:

The Company and its subsidiaries are related to the following legal and natural persons:

- b due to the majority of shares acquisition in its capital with Mr. Georgios Apostolopoulos and the legal persons or other business activities he is related with
- with its subsidiaries including their main shareholders and the members of their Boards of Directors
- with the members of the Company's Board of Directors.

The transactions with its subsidiaries are mainly concerning the provision of commercial services, as well as the purchasing and selling of goods. The transactions are realized within the normal operating framework of the Company.

The relative balances receivable from associates are not covered by securities, mortgages and their payment in full is conducted by cash payment within the time limits agreed between the companies in question. The Management of the Company does not regard that a provision/allowance for a possible non-collection of its subsidiaries related receivables is needed; hence no provision/allowance for doubtful debtors against these receivables is formed.

The balances receivable/(payable) of the related party accounts of the Group are as follows:

Group (subsidiaries)

	Company <i>Debtors</i>	Liabilities	Income	Sales
ATHENS MEDICAL CENTER S.A	0	0	0	0
IATRIKI TECHNIKI S.A.	10	26.286	10	11.788
EREVNA S.A.	0	31	0	0
AXONIKI EREVNA S.A.	0	0	0	0
PHYSIOTHERAPY CENTER S.A.	64	106	64	158
MEDSANA BUCHAREST MEDICAL CENTER	0	0	0	0
BIOAXIS SRL (ex MEDSANA SRL)	0	0	0	0
ORTELIA HOLDINGS	1.686	0	0	0
EUROSITE	2.595	0	0	0
HOSPITAL AFFILLIATES INTERNATIONAL S.A.	327	0	0	0
TOTAL	4.682	26.423	73	11.946
	Company			

Company

	Debtors from dividends	Income from dividends
IATRIKI TECHNIKI S.A.	3.300	3.300
PHYSIOTHERAPY CENTER S.A.	66	66
TOTAL	3.366	3.366

Other(Associates and other companies)

	The Group				The Company			
	Receivables	Liabilities	Income	Purchases	Receivables	Liabilities	Income	Purchases
G. APOSTOLOPOULOS Holdings	2	0	2	0	0	0	0	0
IKODOMIKI EKMETALEFTIKI								
S.A.	5	0	1	0	3	0	0	0
LA VIE Assurance	3.332	64	1.474	4	3.332	64	1.472	4
SYCHRONI ECHODIAGNOSI	0	27	0	0	0	27	0	0
PROSTATE INSTITUTE	0	0	0	0	0	0	0	0
KORINTHIAKOS RYTHMOS	2	397	2	218	0	348	0	171
HERODIKOS Ltd OUS ATH. CENTER OF	33	0	0	0	33	0	0	0
ENVIRONMENT	85	0	0	0	85	0	0	0
TRADOR A.E.	21	0	0	0	21	0	0	0
AGGEIOLOGIKI DIEREVNISI S.A.	0	7	0	0	0	7	0	0
ATHENS PAEDIATRICS CENTER ELECTRONYSTAGMOGRAFIKI	15	0	0	0	15	0	0	0
S.A.	0	0	0	0	0	0	0	0
NEVROLITOURGIKI S.A.	0	0	0	0	0	0	0	0
MEDISOFT	190	0	0	0	190	0	0	0
MEDICAFE CATERING SERVICES S.A.	9	0	52	0	9	0	52	0
DOMINION INSURANCE BROKERAGE S.A.	0	30	0	14	0	30	0	14
INTEROPTICS SA	0	0	0	0	0	0	0	0
I.E. EUROHOSPITAL S.A	0	0	0	0	0	0	0	0
Total	3.695	525	1.531	236	3.688	476	1.524	189

(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

	The Group		The	Company
	Debtors from dividends	Income from dividends	Debtors from dividends	Income from dividends
MEDICAFE CATERING SERVICES S.A.	96	96	0	0
		The	Group	The Company
Compensations of executiv	es and members of the Boar	d 3	.570	3.245
Compensations of member	rs of the Board from profits	4	190	200
-	-	4.	.060	3.445
		The	Group	The Company
Debtors from executives an Liabilities to executives an			10 598	200
Liabilities to executives all	u members of the board		370	400

30. DIVIDENDS

According to the provisions of the greek legislation for companies, they are obliged to distribute every year dividend, that corresponds at least to the 35% of the profits after taxes and the formation of the legal reserve. The non distribution of dividends depends on the approval of the total shareholder company's equity. The greek company legislation requires specific terms for the profit distribution to be satisfied, which are:

- a) Any distribution of dividend is not valid if the company's equity as that appears on the balance Sheet after the distribution is less than equity plus the non distributive reserves
- b) Any distribution of dividend is not valid, if the balance of the formation expenses is greater than the extraordinary reserves plus the retained earnings

At 24 March 2008, the Board of Directors proposed Dividend amounted to 0.06 per share . This proposition of the Board of Directors was approved by the annual General Assembly of the Shareholders of June 27th .

31. CONTIGENCIES AND COMMITMENTS:

(a) Lawsuits/Litigation and claims:

The Company is involved (in its capacity as defendant and as plaintiff) in various lawsuits and legal amperages in the framework of its normal operation. The Management, as well as its legal advisors estimates that all the pending cases are expected to be settled without any significant negative repercussions on the consolidated financial position of the Company or in the results of its operation.

It is noted that the subsidiary "HOSPITAL AFFILIATES INTERNATIONAL", according to no. 246/06 final decision of court to appeal, is obliged to pay to "ERRIKOS DYNAN" the amount of ϵ 207.776 plus interest and other expenses. Against the above decision the company has appealed to Supreme Court. This appeal has been discussed, after postponement, in 8th October 2007 and decision is still expected.

(b) Commitments:

(i) Commitments from operational leases:

The 30th of June 2008 the Group and the Company had various agreements of operational lease, concerning the renting of buildings and transportation equipment and they end in several dates.

The renting expenses are included in the accompanying consolidated income statement of the period ended in the 30th of June 2008 and they amount to \in 952 thous. (\in 1.091 thous. $\tau\eta\nu$ 30th of June 2007)

The minimum future payable rental leases based on non-reversible contracts of operational leases in 30th of June 2008 are as follows:

	30/6/20	008
Commitments from operational leases:	The Group	The Company
Within one year	1.967	2.242
1-5 years	6.266	7.299
After 5 years	2.464	2.300
	10.697	11.841

31/12/2007

Commitments from operational leases:	The Group	The Company
Within one year	2.052	2.029
1-5 years	6.211	6.750
After 5 years	3.302	3.030
	11.565	11.809

(ii) Guarantees:

The Group in 30th of June 2008 had the following contingent liabilities:

Had issued letters of guarantee for good performance for a total amount of € 242 thousand.

32. SUBSEQUENT EVENTS:

There aren't any

Marousi, 25/8/2008

THE PRESIDENT OF THE BOD	THE CHIEF EXECUTIVE OFFICER	THE GROUP CFO	THE PARENT CFO	THE CHIEF ACCOUNTANT
GEORGIOS B. APOSTOLOPOULOS	VASSILIOS G. APOSTOLOPOULOS	ANTONIS H. AGGELOPOULOS	PETROS D. ADAMOPOULOS	PANAGIOTIS X. KATSICHTIS
ID NUMBER Σ 100951	ID NUMBER. £ 350622	ID NUMBER X 143924	ID NUMBER AZ 533419	ID NUMBER. AB 052569 O.E.E. Rank No.17856 Classification A'



ATHENS MEDICAL CENTER S.A.

Reg. No. 13782/06/B/86/06

5-7 Distomou Str, 15125 Maroussi FINANCIAL RESULTS FOR THE PERIOD 1 JANUARY 2008 UNTIL 30 JUNE 2008

According to the 6/448/11.10.2007 decision of the Capital Market's Board of Directors Commission

The following results and information, that arise from the financial statements, provide a general picture of the financial position and financial results of the ATHENS MEDICAL CENTER S.A. Thus we suggest the reader, before entering into any sort of investment decision or other transaction with the issuer, to gain access to the company's web site, where the financial statements can be downloaded, as well as the Auditor's review report when this is required.

COMPANY'S DETAILS

Company's web site: www.iatriko.gr

Date of Approval by the **Board of Director's of interim Financial Statements:** 25 August 2008 **Certified Auditor Accountant:** Vrettos Gerasimou Georgios

Auditing Company : BDO PROTYPOS HELLENIC AUDITING Co. A.E.

Type of Auditor's review report

BALANCE SHEET (con:	BALANCE SHEET (consolidated and non consolidated) amounts in thous. €				CASH FLOW STATEMENT (consolidated and non consolidated) amounts in thous.€				
				Indirect method	GRO)UP	PARENT		
	GR	<u>OUP</u>	PAR	<u>ENT</u>		1/1-30/6/2008	1/1-30/6/2007	1/1-30/6/2008	1/1-30/6/2007
ASSETS	30/6/2008	31/12/2007	30/6/2008	31/12/2007	Operating Activities :				
Property, plant and equipment	281.398	284.119	255.391	259.217	Profit Before Taxes (continued operations)	13.552	17.513	14.453	19.122
Intangible assets	2.342	2.319	340	312	Plus/Less Adjustments for :				
Other non current assets	6.003	5.825	40.592	40.305	Depreciation	5.795	5.491	5.503	5.266
Inventory	6.600	6.789	6.148	6.432	Provisions	1.426	1.154	1.220	1.150
Receivables (trade debtors)	133.338	133.545	132.656	132.859	Exchange Differences	-1	-2	0	0
Other current assets	62.980	58.906	64.890	50.383	Results (revenues, expenses, gain and losses) from				
TOTAL ASSETS	492.661	491.503	500.017	489.508	Investing Activities	-1.912	-1.316	-5.266	-5.511
EQUITY AND LIABILITIES					Interest Expenses and Related costs	6.462	4.216	6.266	4.037
Share capital	26.888	26.888	26.888	26.888	Plus/Less Adjustments for Changes in	0		0.200	
Other components of equity	145.113	140.401	154.285	148.003	Working Capital or Related to Operating				
Total Shareholder Equity (a)	172.001	167.289	181.173	174.891	Activities :				
Non controlling interests (b)	377	398	0		Decrease / Increase in Inventories	188	-324	284	-307
Total Shareholder Equity (c) = $(a)+(b)$	172.378	167.687	181.173	174.891	Decrease / Increase in Receivables	-8.021	-24.685	-8.914	-25.216
Long term borrowings	150.478	157.037	150.141	156.972	Decrease/Increase in Liabilities (except for banks)	-3.253	10.783	5.206	13.884
Long term provisions / Non current liabilities	44.013	42.818	40.632	39.221	Less:	0.200	10.700	0.200	10.004
Short Term borrowings	7.256	11.232	1.840	5.936	Interest charges and Related Expenses Paid	-5.492	-4.216	-5.296	-4.037
Other current liabilities	118.536	112.729	126.231	112.488	Paid Taxes	-737	-4.226	-465	-3.713
Total Liabilities (d)	320.283	323.816	318.844	314.617	Total Inflows / Outflows from	-131	-4.220	-403	-0.710
TOTAL EQUITY AND LIABILITIES (c) + (d)	492.661	491.503	500.017	489.508	Operating Activities (a)	8.007	4.390	12.991	4.673
TOTAL EQUITY AND LIABILITIES (C) + (u)	492.001	491.503	300.017	409.500	Investing Activities :	0.007	4.090	12.991	4.073
					Acquisition of subsidiaries, associates, joint ventures				
					and other investments	-30	0	-30	0
					Purchase of tangible and intangible fixed assets	-3.102	-4.144	-30 -1.709	-3.967
							-4.144	-1.709	-3.907
					Cash collection from the Sale of Tangible and Intangible		44	0	44
					fixed assets	2	11	2	11
					Income from interest	578	44	564	32
STATEMENT OF CHANGES IN EQUITY FO	R THE PERIOD (conso	olidated and non cons	olidated) amounts in	thous. €	Total Inflows / Outflows from			4.480	
					Investing Activities (b)	-2.552	<u>-4.090</u>	1.173	3.924
	GR	OUP	PAI	RENT	Financing Activities :		F 000		F 000
	30/6/2008	30/6/2007	30/6/2008	30/6/2007	Proceeds from Share Capital Increase	0	5.363	0	5.363
Total equity beginning period					Proceeds from Dept	390	15.467	0	14.923
(1/1/2008 and 1/1/2007 accordingly)	167.687	152.984	174.891	158.864	Dept Repayment	-10.526	-19.200	-10.526	-19.116
After tax profit / (loss) for the period	9.896	12.176	11.485	14.549	Payments of Financial Leasing			46-	
(continued and discontinued operations)					(Capital installment)	-400	-1.316	-400	-1.316
Increase / (Decrease) of Share Capital	0	5.363	0	5.363	Dividend Paid	0	-461	0	-2
Dividend Distributed	-5.204	-5.663	-5.204	-5.204	Total Inflows / Outflows from				
Net Income Recorded Directly					Financing Activities (c)	-10.536	-147	-10.926	147
in Equity	-1	-11			Net Increase/Decrease in Cash and Cash Equivalents				
Total equity ending period	·	• •			for the Period (a) $+$ (b) $+$ (c)	<u>-5.081</u>	<u>153</u>	892	602
(30/6/2008 and 30/6/2007 accordingly)	172.378	164.849	181.173	173.572	Cash and Cash Equivalents (beginning)	27.236	8.814	18.580	6.224
(, -, and, -, and, -,					Cash and Cash Equivalents (period end)	22.155	8.966	19.472	6.826

INCOME STATEMENT FOR THE PERIOD (consolidated and non consolidated) amounts in thous. €

<u>unour</u>					PAR	<u>ICIN I</u>		
	<u>1/1-30/6/08</u>	1/1-30/6/07	1/4-30/6/08	<u>1/4-30/6/07</u>	<u>1/1-30/6/08</u>	1/1-30/6/07	1/4-30/6/08	<u>1/4-30/6/07</u>
Turnover	148.078	150.224	73.870	72.230	144.687	147.218	72.184	70.804
Gross Profit	32.726	35.124	15.047	15.994	28.221	30.565	12.807	13.828
Profit before Taxes, Financing and								
Investing Activity	18.103	20.413	6.920	7.795	15.453	17.648	5.879	6.813
Profit before Taxes	13.552	17.513	5.138	6.278	14.453	19.122	6.786	8.657
Profit after Taxes	9.896	12.176	3.494	4.164	11.485	14.549	5.489	6.896
Attributable to :								
Shareholders	9.917	12.096	3.539	4.126	11.485	14.549	5.489	6.896
Non controlling interests	-21	80	-45	38				
Earnings (After Taxes) Per Share - in €	0,1143	0,1429	0,0408	0,0480	0,1324	0,1719	0,0633	0,0807
Profit before Taxes, Financing and								
Investing Activity and depreciation	23.898	25.904	9.824	10.553	20.957	22.914	8.630	9.446

ADDITIONAL INFORMATION:

a) Revenues

b) Expenses

c) Debtors

d) Liabilities

a) Legal disputes b) Tax unaudited years

c) Other provisions

financial statements.

thous. refer to exchange differences.

Group Structure				
Companies	<u>Seat</u>	Participation %	Consolidation	Unaudited Years
			<u>Method</u>	
ATHENS MEDICAL CENTER SA	Maroussi Attica	Parent Co		2007
IATRIKI TECHNIKI SA	Kiffisia Attica	100,00	TOTAL	2007
AKSONIKI EREVNA SA	Maroussi Attica	50,50	TOTAL	2007
EREVNA SA	Maroussi Attica	51,00	TOTAL	2007
PHYSIOTHERAPY CENTER SA	Maroussi Attica	33,00	TOTAL	2007
HOSPITAL AFFILIATES INTERNATIONAL SA	Kiffisia Attica	68,89	TOTAL	2001-2007
MEDSANA BMC	Bucharest Romania	100,00	TOTAL	1997-2007
BIOAXIS SRL (former MEDSANA SRL)	Bucharest Romania	78,90	TOTAL	1997-2007
ORTELIA HOLDING	Lemessos Cyprus	99,99	TOTAL	1998-2007
EUROSITE SA	Maroussi Attica	100,00	TOTAL	2003-2007
MEDICAFE SA	Thessaloniki	55,00	EQUITY METHOD	2003-2007
INTEROPTICS SA	Athens	27,33	EQUITY METHOD	2005-2007
I.E.EUROHOSPITAL SA	Athens	50,00	EQUITY METHOD	

- 1. All companies in the Group are those described in the above table titled "Group Structure". There is no deviation in the Companies and the method of consolidation relative to that used in the financial statements of the respective period of previous year 2007 or the annual financial statements of previous year 2007 with the exemption of company I.E.EUROHOSPITAL SA. I.E.EUROHOSPITAL SA was formed in the a' semester of 2008 and was included in the consolidation of Athens Medical Center SA with the equity method. The effect due to the 10. The profit before taxes, financing, investing activity and the profit before taxes, financing, investing activity and depreciation of the respective consolidation of I.E.EUROHOSPITAL SA in the Group's consolidated figures is of no importance.
- ${\bf 2.}$ There are no pledges against the company's assets and Group's assets.
- 3. There are no legal disputes that could have a significant effect on the company's and the group's financial structure.
- (2.818 first semester of 2007) respectively.
- - 11. The accounting policies applied for these Financial Statements are consistent with those applied for the Financial Statements at 31.12.2007.
- 4. The total number of employees for the first semester of 2008 was : Group 3.155 (2.974 first semester of 2007) and Parent Co 2.987
 - Maroussi, 25 August 2008

The Group CFO Antonios H. Aggelope ID X 143924

The Parent CFO Petros D. Adamopo ID AZ 533419

Commission. Relative report is found in paragraph 3b "Principal accounting policies" note (bd).

5. Profit per share was calculated using the average weighted number of total shares issued. 6. Disclosures of transactions with related parties of Group and Company as defined in IAS 24:

e) Transactions and compensations of executives and members of the Board

f) Debtors from executives and members of the Board

g) Liabilities to executives and members of the Board 7. The amounts of formed provisions are the following:

> The Chief Accountant Panagiotis X. Katsihtis ID AB 052569

GNN 210/8222848

GROUP

1.627

3.791

236

525

10 598

4.060

GROUP

8. The amounts of revenues / expenses recorded directly in Group's equity for periods 1/1-30/6/2008 € -1 thous. and 1/1-30/6/2007 € -11

9. A detailed report to Group's structure is found in paragraphs 2, 3b "Principal accounting policies" as well as in paragraphs 15 and 16 of the

period of 2007, for Company and Group have been reformed according to decision 34/24.1.2008 of the Capital Market's Board of Director's

490

0

PARENT

4.963

12.135

11.736

26 899

3.445

200

400

0

PARENT